日本臨牀　81/増刊7　ウイルス性肝炎学　2023

出版社： 日本臨牀社
発行日： 2023-07-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： ウイルス性肝炎学　2023
電子書籍版： 2023-07-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

24,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

24,200 円(税込)

購入する

目次

  • 特集　ウイルス性肝炎学　2023
    　　　―最新の病態・診断・治療情報―

    I．総　論
    　１．ウイルス性肝炎発見の歴史
    　２．肝炎ウイルスの種類
    　３．ウイルス肝炎検査・診断の変遷と展望
    　４．ウイルス性肝炎治療の変遷と展望
    　５．C型慢性肝疾患治療のeliminationに向けて
    　６. B型肝炎治療の進展と問題点
    　７. ウイルス肝炎からの肝発癌

    II．ウイルス性肝炎の病理：総論
    　１．ウイルス性肝炎の病理：総論

    III．肝炎ウイルス研究の進歩
    　１．培養細胞を用いた肝炎ウイルス複製
    　　（１）HCVレプリコン
    　　（２）肝炎ウイルス培養系と抗ウイルス薬開発への応用
    　２．肝炎ウイルス感染動物モデル
    　　（１）B型肝炎ウイルスの動物モデルと治療開発

    IV．肝炎ウイルスマーカー測定の意義
    　１．C型肝炎ウイルスマーカー測定の意義
    　２.　B型肝炎ウイルスマーカー測定の意義

    V．各　論
    　１．C型肝炎
    　　（１）日本におけるC型肝炎の疫学　 国際比較-
    　　（２）C型肝炎ウイルス(HCV)の感染と肝炎発症機序
    　　　　１）HCV感染の最近の動向
    　　　　２）薬物使用とHCV感染
    　　　　３）C型肝炎発症機序
    　　　　４）C型肝炎ウイルスの複製増殖機構
    　　（３）ウイルス排除をめざした臨床研究
    　　　　１）C型肝炎の治療と生命予後
    　　　　２）多剤耐性例の出現とその対策
    　　　　３）DAAを用いたC型非代償性肝硬変症例に対する抗ウイルス治療
    　　　　４）抗ウイルス療法の治療効果予測と宿主因子
    　　　　５）ウイルス学的超難治例の形成機序
    　　　　６）高齢者に対する抗ウイルス治療の問題点
    　　（４）検査・診断
    　　　　１）C型肝炎の診断(臨床検査を中心に)
    　　　　２）非侵襲的肝線維化診断法：腹部超音波エラストグラフィとMRエラストグラフィ
    　　　　３）肝線維化マーカーを用いた線維化評価
    　　（５）治　療
    　　　　１）C型慢性肝炎合併透析症例に対する抗ウイルス療法
    　　　　２）HIVとHCVとの重複感染
    　　　　３）肝移植前後のC型肝炎に対する治療
    　　　　４）肝癌再発予防を目指した抗ウイルス療法
    　　　　５） C型慢性肝疾患での肝外病変とその対策
    　２．B型肝炎
    　　（１）日本におけるB型肝炎の疫学　 国際比較-
    　　（２）B型急性肝炎の動向：概論
    　　（３）B型慢性肝炎の動向：概論
    　　（４）B型急性肝不全の動向: 概論
    　　（５）B型肝炎ウイルス(HBV)の分子生物学と肝炎発症機序
    　　　　１）HBVの遺伝子構造、複製機構
    　　　　２）HBVの持続感染因子
    　　　　３）B型肝炎発症機序
    　　　　４）HBVの肝細胞障害
    　　（６）臨床をめざした基礎研究
    　　　　１）HBVの細胞内侵入機構と創薬標的
    　　　　２）HBV遺伝子型・遺伝子変異
    　　　　３）HBVによる肝発癌機構の研究
    　　　　４）ヒト肝細胞キメラマウスを用いたin vivoおよびin vitro HBV感染モデル
    　　　　５）HBV感染に対する免疫応答機構
    　　　　６）HBVゲノムのインテグレーション
    　　　　７）HBxタンパクの機能とウイルスの複製
    　　　　８）獲得免疫によるcccDNAの制御
    　　　　９）ゲノム編集によるcccDNAの破壊
    　　（７）病　態
    　　　　１）B型肝炎の自然経過と予後
    　　　　２）B型肝炎の発症機序と病態
    　　　　３）HBV遺伝子型と臨床像
    　　　　４）HBVの変異と病態
    　　（８）B型慢性肝炎の病態・治療・予後に関連する因子(HLA-DP)
    　　（９）臨床研究
    　　　　１）HBV再活性化対策
    　　　　２）オリゴヌクレオチドによるB型慢性肝疾患治療
    　　　　３）核酸アナログ長期投与とHBV-DNA陰性化
    　　　　４）核酸アナログ製剤治療によるHBs抗原陰性化と発癌
    　　　　５）B型慢性肝炎に対するペグインターフェロン単独療法と核酸アナログ併用療法
    　　　　６）核酸アナログ製剤中止時のPeg-IFNα Sequential療法の効果と安全性
    　　　　７）放射線被曝と肝炎ウイルス感染の肝細胞癌リスク
    　　（10）検査・診断
    　　　　１）基本的な検査・診断と注意事項
    　　　　２）HBV関連分子とその臨床的意義
    　　　　３）HBV検査マーカーの有用性
    　　（11）治　療
    　　　　１）B型慢性肝炎の自然経過と治療の選択
    　　　　２）B型慢性肝炎に対するペグインターフェロン療法
    　　　　３）核酸アナログ療法
    　　　　４）シーケンシャル療法
    　　　　５）B型慢性肝炎におけるHBe抗原の意義
    　　　　６）HBs抗原陰性化を目指した治療
    　　　　７）新規抗HBV薬剤の開発状況
    　　（12）特殊病態下でのB型肝炎に対する対応
    　　　　１）抗悪性腫瘍薬，免疫抑制薬によるHBV再活性化とその対策
    　　　　２）肝移植後のHBV再活性化とその対応
    　　　　３）HBV・HIV重複感染症
    　　（13）抗ウイルス療法によるB型肝炎の発癌および再発抑制効果
    　　（14）B型肝炎ウイルス感染とその予防対策
    　３．A型肝炎
    　　（１）A型肝炎ウイルス(HAV) の疫学
    　　（２）A型肝炎ウイルスのウイルス学的特徴
    　　（３）A型急性肝炎の臨床的特徴
    　　（４）診断・治療
    　　（５）A型肝炎の予防
    　４．デルタ(D型)肝炎
    　　（１）デルタ(D型)肝炎の疫学
    　　（２）デルタ(D型)肝炎のサブタイプと特徴
    　　（３）デルタ(D型)肝炎 診断・治療
    　５．E型肝炎
    　　（１）E型肝炎ウイルスの疫学
    　　（２）E型肝炎ウイルスのウイルス学的特徴
    　　（３）E型肝炎の臨床的特徴
    　　（４）E型肝炎の診断および治療
    　　（５）E型肝炎の予防
    　6．肝炎ウイルス以外のウイルスによる肝炎
    　　（１）肝炎ウイルス以外のウイルスによる肝炎：総論
    　　（２）単純ヘルペスウイルス
    　　（３）EBウイルス
    　　（４）サイトメガロウイルス

    VI．特　論
    　１．B型肝炎ウイルスの発癌リスク因子
    　２．ウイルス性肝炎患者拾い上げの問題
    　３．B型肝炎ワクチンの定期接種化の意義と課題
    　４．小児B型慢性肝炎に対する治療
    　５．E型肝炎ウイルスの感染経路　ブタ肉加工品及びその他
    　６．輸血用血液の肝炎対策─血液スクリーニングの現況─

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.4 掲載の参考文献
1) Choo QL, Kuo G, Weiner AJ, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Andani A, van Damme P, Bunge EM, et al:One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020:A systematic review. Vaccine 40:196-205, 2022.
PubMed
3) Spada E, Costantino A, Pezzotti P, et al:Hepatitis E virus infection prevalence among men who have sex with men involved in a hepatitis A virus outbreak in Italy. Blood Transfus 17:428-432, 2019.
 
4) Zhu FC, Zhang J, Zhang XF, et al:Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults:a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376:895-902, 2010.
 

I 総論

P.11 掲載の参考文献
1) Findlay GM, MacCallum FO:Hepatitis and Jaundice Associated with Immunization against Certain Virus Diseases:(Section of Comparative Medicine). Proc R Soc Med 31:799-806, 1938.
PubMed
2) MacCallum FO, Miles JA:A transmissible disease in rats inoculated with material from cases of infective hepatitis. Lancet 1:3-5, 1946.
PubMed
3) Blumberg BS, Alter HJ, Visnich S:A "new" antigen in leukemia sera. JAMA 191:541-546, 1965.
PubMed
4) Okochi K, Murakami S:Observations on Australia antigen in Japanese. Vox Sang 15:374-385, 1968.
 
5) Prince AM:An antigen detected in the blood during the incubation period of serum hepatitis. Proc Natl Acad Sci USA 60:814-821, 1968.
PubMed
6) Dane DS, Cameron CH, Briggs M:Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1:695-698, 1970.
PubMed
7) Galibert F, Mandart E, Fitoussi F, et al:Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 281:646-650, 1979.
 
8) Valenzuela P, Medina A, Rutter WJ, et al:Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 298:347-350, 1982.
PubMed
9) Feinstone SM, Kapikian AZ, Purceli RH:Hepatitis A:detection by immune electron microscopy of a viruslike antigen associated with acute illness. Science 182:1026-1028, 1973.
PubMed
10) Rizzetto M, Canese MG, Arico S, et al:Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut 18:997-1003, 1977.
PubMed
11) Balayan MS, Andjaparidze AG, Savinskaya SS, et al:Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology 20:23-31, 1983.
PubMed
12) Choo QL, Kuo G, Weiner AJ, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
13) Alter HJ, Purcell RH, Shih JW, et al:Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494-1500, 1989.
PubMed
14) Miyamura T, Saito I, Katayama T, et al:Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA:application to diagnosis and blood screening for posttransfusion hepatitis. Proc Natl Acad Sci USA 87:983-987, 1990.
PubMed
15) Kato N, Hijikata M, Ootsuyama Y, et al:Molecular cloning of the human hepatitis C virus genome from Japanese patients with 350non-A, non-B hepatitis. Proc Natl Acad Sci USA 87:9524-9528, 1990.
PubMed
P.18 掲載の参考文献
1) 杉山隆一, 清原知子, 鈴木亮介, ほか:2018年のA型肝炎流行状況について. IASR 40:150-151, 2019. [https://www.niid.go.jp/niid/ja/typhi-m/iasr-reference/2469-related-articles/related-articles-475/9115-475r02.html]
 
2) 井上貴子, 加治屋幹人, 加藤正美, ほか:歯科医師のB型肝炎ワクチン接種状況にみられる問題点. 肝臓 64:150-151, 2023.
 
3) Mizokami M, Yokosuka O, Takehara T, et al:Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C:an open-label, randomised, phase 3 trial. Lancet Infect Dis 15:645-653, 2015.
PubMed
4) Korenaga M, Murata K, Izumi N, et al:No increased risk of hepatocellular carcinoma after eradication of hepatitis C virus by direct-acting antivirals, compared with interferon-based therapy. Glob Health Med 4:216-224, 2022.
PubMed
5) 肝炎治療促進事業【資料】令和3年度肝炎医療費助成対象者数調査票. [https://www.mhlw.go.jp/content/10900000/r03josei_taisyou.pdf]
 
6) 厚生労働省/国立感染症研究所:感染症週報IDWR(Infectious Diseases Weekly Report Japan)2021年第41週(10月11日～10月17日):通巻第23巻第41号. [https://www.niid.go.jp/niid/images/idsc/idwr/IDWR2021/idwr2021-41.pdf]
 
P.26 掲載の参考文献
1) Cuthbert JA:Hepatitis A:old and new. Clin Microbiol Rev 14:38-58, 2001.
PubMed
2) Watanabe S, Morimoto N, Miura K, et al:Full-genome characterization of the RIVM-HAV16-090-like hepatitis A virus strains recovered from Japanese men who have sex with men, with sporadic acute hepatitis A. Hepatol Res 49:521-530, 2019.
PubMed
3) Kamar N, Selves J, Mansuy JM, et al:Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358:811-817, 2008.
PubMed
4) Chauhan A, Jameel S, Dilawari JB, et al:Hepatitis E virus transmission to a volunteer. Lancet 341:149-150, 1993.
PubMed
5) Bryan JP, Tsarev SA, Iqbal M, et al:Epidemic hepatitis E in Pakistan:patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. J Infect Dis 170:517-521, 1994.
 
6) Takahashi M, Kusakai S, Mizuo H, et al:Simultaneous detection of immunoglobulin A (IgA) and IgM antibodies against hepatitis E virus (HEV) Is highly specific for diagnosis of acute HEV infection. J Clin Microbiol 43:49-56, 2005.
PubMed
7) Orito E, Ichida T, Sakugawa H, et al:Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
8) Kao JH, Chen PJ, Lai MY, et al:Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334, 2003.
PubMed
9) Inoue T, Kusumoto S, Iio E, et al:Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 75:302-310, 2021.
PubMed
10) Watanabe T, Inoue T, Tanaka Y:Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 9:2083, 2021.
 
11) Wong DK, Tanaka Y, Lai CL, et al:Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol 45:3942-3947, 2007
PubMed
12) Tanaka E, Matsumoto A, Suzuki F, et al:Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 26:90-96, 2006.
PubMed
13) Shinkai N, Tanaka Y, Orito E, et al:Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 36:272-276, 2006.
PubMed
14) Hosaka T, Suzuki F, Kobayashi M, et al:Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir. Hepatol Commun 6:36-49, 2022.
PubMed
15) WHO fact sheet, Hepatitis C. [https://www.who.int/news-room/fact-sheets/detail/hepatitis-c]
 
16) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
17) Tanaka Y, Takagi K, Fujihara T, et al:High stability of enzyme immunoassay for hepatitis C virus core antigen-evaluation before and after incubation at room temperature. Hepatol Res 26:261-267, 2003.
PubMed
P.31 掲載の参考文献
1) Kumada H, Ikeda K, Yoshida A, et al:Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B. Jpn J Med 26:217-222, 1987.
PubMed
2) Wong DK, Cheung AM, O'Rourke K, et al:Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312-323, 1993.
PubMed
3) Cooksley WG, Piratvisuth T, Lee SD, et al:Peginterferon alpha-2a (40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepatit 10:298-305, 2003.
 
4) Marcellin P, Lau GK, Bonino F, et al:Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351:1206-1217, 2004.
PubMed
5) Hashimoto Y, Suzuki F, Hirakawa M, et al:Clinical and virological effects of long-term (over 5 years)lamivudine therapy. J Med Virol 82:684-691, 2010.
PubMed
6) Yokosuka O, Takaguchi K, Fujioka S, et al:Long-term use of entecavir in nucleotide-naive Japanese patients with chronic hepatitis B infection. J Hepatol 52:791-799, 2010.
 
7) Buti M, Gane E, Seto WK, et al:Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection:a randomized, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterolo Hepatol 1:196-206, 2016.
 
8) 鈴木文孝:核酸アナログ製剤による治療. HEPATOLOGY PRACTICE1 B型肝炎の診療を極める(田中榮司, 竹原徹郎, 持田 智 編), p104-109, 文光堂, 2013.
 
9) 渡辺丈久, 田中靖人:B型肝炎の創薬. 消化器内科レビュー2022-'23(竹原徹郎 監), p148-154, 総合医学社, 2022.
 
10) Kuo G, Choo QL, Alter HJ, et al:An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989.
 
11) 濱野耕靖:インターフェロン単独24週間療法の治療効果. ここがポイントC型・B型肝炎, 肝癌の診療(泉 並木 編), p37-42, 南江堂, 2008.
 
12) Oze T, Hiramatsu N, Yakushijin T, et al:The efficacy of extended treatment with pegylated interferon plus ribavirin in patients with HCV genotype 1 and slow virologic response in Japan. J Gastroenterol 46:944-952, 2011.
PubMed
13) C型肝炎治療ガイドライン[第8.2版](日本肝臓学会肝炎診療ガイドライン作成委員会 編), 2023.
 
14) Akuta N, Suzuki F, Hirakawa M, et al:Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52:421-429, 2010.
PubMed
15) Hayashi N, Izumi N, Kumada H, et al:Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan:CONCERTO-1, a phase III trial. J Hepatol 61:219-227, 2014.
PubMed
16) Suzuki Y, Ikeda K, Suzuki F, et al:Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 58:655-662, 2013.
PubMed
17) Mizokami M, Yokosuka O, Takehara T, et al:Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C:an open-label, randomised, phase 3 trial. Lancet Infect Dis 15:645-653, 2015.
PubMed
18) Sezaki H, Suzuki F, Hosaka T, et al:Initial-and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 54:916-927, 2019.
PubMed
19) Izumi N, Takehara T, Chayama K, et al:Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12:356-367, 2018.
PubMed
20) Omata M, Nishiguchi S, Ueno Y, et al:Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection:an open-label, phase 3 trial. J Viral Hepat 21:762-768, 2014.
 
P.38 掲載の参考文献
1) Asselah T, Marcellin P, Schinazi RF:Treatment of hepatitis C virus infection with direct-acting antiviral agents:100% cure? Liver Int 38(Suppl 1):7-13, 2018.
 
2) World Health Organization:Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. [https://www.who.int/publications/i/item/9789240027077]
 
3) Thomas DL:Global Elimination of Chronic Hepatitis. N Engl J Med 380:2041-2050, 2019.
PubMed
4) Foreman KJ, Marquez N, Dolgert A, et al:Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death:reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet 392:2052-2090, 2018.
PubMed
5) World Health Organization:Global Hepatitis Report, 2017. [https://www.who.int/publications/i/item/9789241565455]
 
6) Riedel S:Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18:21-25, 2005.
 
7) Yanagi M, Purcell RH, Emerson SU, et al:Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc Natl Acad Sci USA 94:8738-8743, 1997.
PubMed
8) Kolykhalov AA, Agapov EV, Blight KJ, et al:Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570-574, 1997.
PubMed
9) Xu X, Chen H, Cao X, et al:Efficient infection of tree shrew (Tupaia belangeri) with hepatitis C virus grown in cell culture or from patient plasma. J Gen Virol 88:2504-2512, 2007.
PubMed
10) Catanese MT, Dorner M:Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Virology 479-480:221-233, 2015.
 
11) Takikawa S, Engle RE, Faulk KN, et al:Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins. J Gen Virol 91:727-733, 2010.
PubMed
12) Suzuki S, Mori K, Higashino A, et al:Persistent replication of a hepatitis C virus genotype 1b-based chimeric clone carrying E1, E2 and p6 regions from GB virus B in a New World monkey. Microbiol Immunol 60:26-34, 2016.
 
13) Li T, Zhu S, Shuai L, et al:Infection of common marmosets with hepatitis C virus/GB virus-B chimeras. Hepatology 59:789-802, 2014.
 
14) Billerbeck E, Wolfisberg R, Fahnoe U, et al:Mouse models of acute and chronic hepacivirus infection. Science 357:204-208, 2017.
PubMed
15) Berggren KA, Suzuki S, Ploss A:Animal Models Used in Hepatitis C Virus Research. Int J Mol Sci 21:3869, 2020.
PubMed
P.44 掲載の参考文献
1) B型肝炎治療ガイドライン(第4版)(日本肝臓学会肝炎診療ガイドライン作成委員会 編), 2022. [https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v4.pdf]
 
2) Hosaka T, Suzuki F, Kobayashi M, et al:Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98-107, 2013.
PubMed
3) Ono A, Suzuki F, Kawamura Y, et al:Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol 57:508-514, 2012.
PubMed
4) Suzuki F, Hosaka T, Suzuki Y, et al:Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol 54:182-193, 2019.
PubMed
5) Yeo YH, Ho HJ, Yang HI, et al:Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection:A Systematic Review and Meta-analysis. Gastroenterology 156:635-646. e9, 2019.
 
6) Suzuki F, Arase Y, Suzuki Y, et al:Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan. J Gastroenterol 47:814-822, 2012.
PubMed
7) Hosaka T, Suzuki F, Kobayashi M, et al:Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B:results from a nine-year longitudinal study. J Gastroenterol 48:930-941, 2013.
PubMed
8) Brouwer WP, Xie Q, Sonneveld MJ, et al:Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B:A multicenter randomized trial (ARES study). Hepatology 61:1512-1522, 2015.
PubMed
9) Matsumoto A, Nishiguchi S, Enomoto H, et al:Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol 53:247-257, 2018.
PubMed
P.50 掲載の参考文献
1) 国立がん研究センターがん情報サービス「がん統計」(全国がん登録)[https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#a14]
 
2) Yoshizawa H:Hepatocellular carcinoma associated with hepatitis C virus infection in Japan:projection to other countries in the foreseeable future. Oncology 62(Suppl 1):8-17, 2002.
 
3) 山岡 義, 猪飼 伊, 有井 滋, ほか:第16回全国原発性肝癌追跡調査報告(2000～2001)(日本肝癌研究会追跡調査委員会). 肝臓 46:234-254, 2005.
 
4) Nakagomi R, Tateishi R, Masuzaki R, et al:Liver stiffness measurements in chronic hepatitis C:Treatment evaluation and risk assessment. J Gastroenterol Hepatol 34:921-928, 2019.
PubMed
5) Carrat F, Fontaine H, Dorival C, et al:Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment:a prospective cohort study. Lancet 393:1453-1464, 2019.
PubMed
6) Chen CJ, Yang HI, Su J, et al:Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295:65-73, 2006.
 
7) Jung KS, Kim SU, Ahn SH, et al:Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 53:885-894, 2011.
PubMed
8) Liaw YF, Sung JJ, Chow WC, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
9) Hosaka T, Suzuki F, Kobayashi M, et al:Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98-107, 2013
PubMed

II ウイルス性肝炎の病理 : 総論

P.58 掲載の参考文献
1) Theise ND, Bodenheimer HC, Guido M:Viral hepatitis. In:MacSween's Pathology of the Liver, 7th ed (ed by Burt AD, Ferrel LD, Hubscher SG), p372-415, Elsevier, Amsterdam, 2017.
 
2) Poff JA, Coakley FV, Qayyum A, et al:Frequency and histopathologic basis of hepatic surface nodularity in patients with fulminant hepatic failure. Radiology 249:518-523, 2008.
PubMed
3) Kojiro M, Shimamatsu K, Kage M:Pathomorphologic comparison of hepatitis C virus-related and hepatitis B virus-related cirrhosis bearing hepatocellular carcinoma. Princess Takamatsu Symp 25:179-184, 1995.
PubMed
4) Wanless IR, Nakashima E, Sherman M:Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 124:1599-1607, 2000.
PubMed
5) Fang JW, Wright TL, Lau JY:Fibrosing cholestatic hepatitis in patient with HIV and hepatitis B. Lancet 342:1175, 1993.
PubMed
6) Knodell RG, Ishak KG, Black WC, et al:Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431-435, 1981.
PubMed
7) Ishak K, Baptista A, Bianchi L, et al:Histological grading and staging of chronic hepatitis. J Hepatol 22:696-699, 1995.
PubMed
8) Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20:15-20, 1994.
 
9) Ichida F, Tsuji T, Omata M, et al:New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6:112-119, 1996.
 

III 肝炎ウイルス研究の進歩

P.64 掲載の参考文献
1) Lohmann V, Korner F, Koch J, et al:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113, 1999.
 
2) Moradpour D, Penin F, Rice CM:Replication of hepatitis C virus. Nat Rev Microbiol 5:453-463, 2007.
PubMed
3) Khan S, Soni S, Veerapu NS:HCV Replicon Systems:Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 10:325, 2020.
PubMed
4) Ikeda M, Yi M, Li K, et al:Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 76:2997-3006, 2002.
 
5) Kato T, Date T, Miyamoto M, et al:Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817, 2003.
PubMed
6) Saeed M, Gondeau C, Hmwe S, et al:Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144:56-58. e7, 2013.
 
7) Saeed M, Scheel TK, Gottwein JM, et al:Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob Agents Chemother 56:5365-5373, 2012.
PubMed
8) Wose Kinge CN, Espiritu C, Prabdial-Sing N, et al:Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents. Antimicrob Agents Chemother 58:5386-5394, 2014.
PubMed
9) Yu M, Peng B, Chan K, et al:Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 58:2638-2646, 2014.
PubMed
10) Krieger N, Lohmann V, Bartenschlager R:Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 75:4614-4624, 2001.
PubMed
11) Lohmann V, Hoffmann S, Herian U, et al:Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J Virol 77:3007-3019, 2003.
PubMed
12) Saeed M, Andreo U, Chung HY, et al:SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524:471-475, 2015.
PubMed
13) Blight KJ, McKeating JA, Marcotrigiano J, et al:Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J Virol 77:3181-3190, 2003.
PubMed
14) Murray EM, Grobler JA, Markel EJ, et al:Persistent replication of hepatitis C virus replicons expressing the beta-lactamase reporter in subpopulations of highly permissive Huh7 cells. J Virol 77:2928-2935, 2003.
 
15) Moradpour D, Evans MJ, Gosert R, et al:Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol 78:7400-7409, 2004.
PubMed
P.71 掲載の参考文献
1) Wakita T, Pietschmann T, Kato T, et al:Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791-796, 2005.
PubMed
2) Saeed M, Andreo U, Chung HY, et al:SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 524:471-475, 2015.
PubMed
3) Miyayama Y, Lee H, Song H, et al:Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs. Microbiol Immunol 64:296-303, 2020.
 
4) Yan H, Zhong G, Xu G, et al:Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 3:e00049, 2012.
 
5) Iwamoto M, Saso W, Sugiyama R, et al:Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci USA 116:8487-8492, 2019.
PubMed
6) Li YY, Kuroki K, Shimakami T, et al:Hepatitis B Virus Utilizes a Retrograde Trafficking Route via the Trans-Golgi Network to Avoid Lysosomal Degradation. Cell Mol Gastroenterol Hepatol 15:533-558, 2023.
PubMed
7) Gripon P, Rumin S, Urban S, et al:Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 99:15655-15660, 2002.
PubMed
8) Ishida Y, Yamasaki C, Yanagi A, et al:Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. Am J Pathol 185:1275-1285, 2015.
PubMed
9) Sakurai F, Mitani S, Yamamoto T, et al:Human induced-pluripotent stem cell-derived hepatocyte-like cells as an in vitro model of human hepatitis B virus infection. Sci Rep 7:45698, 2017.
 
10) Akahori Y, Kato H, Fujita T, et al:Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes. Sci Rep 10:21718, 2020.
PubMed
11) Takayama K, Kawabata K, Nagamoto Y, et al:3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34:1781-1789, 2013.
PubMed
12) Takebe T, Sekine K, Enomura M, et al:Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499:481-484, 2013.
PubMed
13) Camp JG, Sekine K, Gerber T, et al:Multilineage communication regulates human liver bud development from pluripotency. Nature 546:533-538, 2017.
PubMed
14) Jang KJ, Otieno MA, Ronxhi J, et al:Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci Transl Med 11:eaax5516, 2019.
PubMed
15) Ortega-Prieto AM, Skelton JK, Cherry C, et al:"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection. J Vis Exp, 2019. (DOI:10. 3791/58333)
 
P.74 掲載の参考文献
1) Bissig KD, Wieland SF, Tran P, et al:Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest 120:924-930, 2010.
 
2) Azuma H, Paulk N, Ranade A, et al:Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice. Nat Biotechnol 25:903-910, 2007.
PubMed
3) Kosaka K, Hiraga N, Imamura M, et al:A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections. Biochem Biophys Res Commun 441:230-235, 2013.
 
4) Tateno C, Miya F, Wake K, et al:Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest 93:54-71, 2013.
PubMed
5) Uchida T, Imamura M, Hayes CN, et al:Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. Antimicrob Agents Chemother 61:e00725-17, 2017.
PubMed
6) Uchida T, Hiraga N, Imamura M, et al:Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice. J Virol 89:10087-10096, 2015.
PubMed
7) Brehm MA, Kenney LL, Wiles MV, et al:Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J 33:3137-3151, 2019.
PubMed
8) Shultz LD, Saito Y, Najima Y, et al:Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice. Proc Natl Acad Sci USA 107:13022-13027, 2010
 

IV 肝炎ウイルスマーカー測定の意義

P.80 掲載の参考文献
1) Choo QL, Kuo G, Weiner AJ, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Kuo G, Choo QL, Alter HJ, et al:An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989.
 
3) C型肝炎治療ガイドライン(第8.2版)(日本肝臓学会肝炎診療ガイドライン作成委員会 編), 2023. [http://www.jsh.or.jp/medical/guidelines/jsh_guidlines]
 
P.86 掲載の参考文献
1) B型肝炎治療ガイドライン(第4版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2022.
 
2) Schweitzer A, Horn J, Mikolajczyk RT, et al:Estimations of worldwide prevalence of chronic hepatitis B virus infection:a systematic review of data published between 1965 and 2013. Lancet 386:1546-1555, 2015.
PubMed
3) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
4) Usuda S, Okamoto H, Iwanari H, et al:Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 80:97-112, 1999.
PubMed
5) Liaw YF, Sheen IS, Chen TJ, et al:Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection:a prospective study. Hepatology 13:627-631, 1991.
PubMed
6) Matsumoto A, Imaizumi M, Tanaka Y, et al:Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol 52:376-384, 2017.
PubMed
7) Inoue T, Kusumoto S, Iio E, et al:Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 75:302-310, 2021.
PubMed
8) Suzuki T, Inoue T, Matsuura K, et al:Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation. J Gastroenterol 57:486-494, 2022.
PubMed
9) Kimura T, Rokuhara A, Sakamoto Y, et al:Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 40:439-445, 2002.
PubMed
10) Rokuhara A, Tanaka E, Matsumoto A, et al:Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 10:324-330, 2003.
PubMed
11) Suzuki F, Miyakoshi H, Kobayashi M, et al:Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81:27-33, 2009.
PubMed
12) Watanabe T, Inoue T, Tanaka Y:Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 9:2083, 2021.
 
13) Shinkai N, Tanaka Y, Orito E, et al:Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 36:272-276, 2006.
PubMed
14) Tanaka E, Matsumoto A, Suzuki F, et al:Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 26:90-96, 2006.
PubMed
15) Tanaka E, Matsumoto A:Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res 44:1-8, 2014. (DOI:10. 1111/hepr. 12108)
 
16) Tada T, Kumada T, Toyoda H, et al:HBcrAg predicts hepatocellular carcinoma development:An analysis using time-dependent receiver operating characteristics. J Hepatol 65:48-56, 2016.
PubMed
17) Tseng TC, Liu CJ, Hsu CY, et al:High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Gastroenterology 157:1518-1529. e3, 2019.
 
18) Tseng TC, Hosaka T, Liu CJ, et al:Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase. Am J Gastroenterol 117:748-757, 2022.
PubMed
19) Honda M, Shirasaki T, Terashima T, et al:Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis 213:1096-1106, 2016.
PubMed
20) Kumada T, Toyoda H, Tada T, et al:Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:a propensity score analysis. J Hepatol 58:427-433, 2013.
 
21) Liang LY, Wong VW, Toyoda H, et al:Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol 55:899-908, 2020.
PubMed
22) Cheung KS, Seto WK, Wong DK, et al:Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat 24:654-661, 2017.
PubMed
23) Suzuki F, Hosaka T, Imaizumi M, et al:Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Hepatol Res 51:426-435, 2021.
PubMed
24) Hagiwara S, Kusumoto S, Inoue T, et al:Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay. Hepatol Res 52:745-753, 2022.
PubMed

V 各論

P.98 掲載の参考文献
1) Choo QL, Kuo G, Weiner AJ, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Kuo G, Choo QL, Alter HJ, et al:An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362-364, 1989.
 
3) World Health Organization:Hepatitis C. (Global Alert and Response, 2002) , World Health Organization, Geneva, 2002.
 
4) WHO:Global Hepatitis Report, 2017. World Health Organization, Geneva, 2017.
 
5) Gower E, Estes C, Blach S, et al:Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45-S57, 2014.
PubMed
6) WHO:Hepatitis C. [https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c]
 
7) World Health Organization:Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. [https://www.who.int/publications/i/item/9789240027077]
 
8) Tanaka J, Kumagai J, Katayama K, et al:Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 47:32-40, 2004.
 
9) Tanaka J, Koyama T, Mizui M, et al:Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology 54:185-195, 2011.
 
10) Tanaka J, Akita T, Ohisa M, et al:Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 25:363-372, 2018.
PubMed
11) Ko K, Akita T, Satake M, et al:Epidemiology of viral hepatitis C:Road to elimination in Japan. Glob Health Med 3:262-269, 2021.
PubMed
12) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
13) Polaris Observatory HCV Collaborators:Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020:a modelling study. Lancet Gastroenterol Hepatol 7:396-415, 2022.
PubMed
14) 医薬品販売実績データベース(IQVIA)に基づく肝炎治療の実態把握と課題の抽出(研究代表者:田中純子), 厚生労働科学研究費補助金(肝炎等克服政策研究事業)令和4年度報告書「肝炎ウイルス感染状況の把握及び肝炎ウイルス排除への方策に資する疫学研究」, 2022.
 
15) Do SH, Yamada H, Fujimoto M, et al:High prevalences of hepatitis B and C virus infections among adults living in Binh Thuan province, Vietnam. Hepatol Res 45:259-268, 2015.
 
16) Matsuo J, Do SH, Yamamoto C, et al:Clustering infection of hepatitis B virus genotype B4 among residents in Vietnam, and its genomic characters both intra- and extra-family PLoS One 12:e0177248, 2017.
PubMed
17) Yamada H, Fujimoto M, Svay S, et al:Seroprevalence, genotypic distribution and potential risk factors of hepatitis B and C virus infections among adults in Siem Reap, Cambodia. Hepatol Res 45:480-487, 2015.
 
18) Ork V, Woodring J, Hossain MD, et al:Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017. Vaccine 37:5059-5066, 2019.
 
19) E B, Ko K, Nagashima S, et al:Dried blood spot-based detection of serological profiles of hepatitis B and C infections and their prevalence in Cambodia. GastroHep 3:247-253, 2021.
 
20) Lingani M, Akita T, Ouoba S, et al:The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso:a random sampling survey. BMC Infect Dis 20:46, 2020.
 
21) Hussain MRA, Hiebert L, Sugiyama A, et al:Effect of COVID-19 on hepatitis B and C virus countermeasures:Hepatologist responses from nationwide survey in Japan. Hepatol Res 52:899-907, 2022.
 
P.104 掲載の参考文献
1) 国立感染症研究所:急性C型肝炎 2006年4月～2020年10月. 病原微生物検出情報 (月報) 42:1-2, 2021.
 
2) Terrault NA, Dodge JL, Murphy EL, et al:Sexual transmission of hepatitis C virus among monogamous heterosexual couples:the HCV partners study. Hepatology 57:881-889, 2013.
PubMed
3) Vandelli C, Renzo F, Romano L, et al:Lack of evidence of sexual transmission of hepatitis C among monogamous couples:results of a 10-year prospective follow-up study. Am J Gastroenterol 99:855-859, 2004.
PubMed
4) Nakashima K, Kashiwagi S, Hayashi J, et al:Sexual transmission of hepatitis C virus among female prostitutes and patients with sexually transmitted diseases in Fukuoka, Kyushu, Japan. Am J Epidemiol 136:1132-1137, 1992.
PubMed
5) Ryerson AB, Schillie S, Barker LK, et al:Vital Signs:Newly Reported Acute and Chronic Hepatitis C Cases-United States, 2009-2018. MMWR Morb Mortal Wkly Rep 69:399-404, 2020.
PubMed
6) 嶋根卓也, 邱 冬梅, 和田 清:薬物使用に関する全国住民調査(2017年). 厚生労働科学研究費補助金(医薬品・医療機器等レギュラトリーサイエンス政策研究事業)「薬物乱用・依存状況等のモニタリング調査と薬物依存症者・家族に対する回復支援に関する研究」平成29年度 総括・分担研究報告書(研究代表者:嶋根卓也), p7-148, 国立精神・神経医療研究センター 精神保健研究所, 2018.
 
7) 松本俊彦, 伊藤 翼, 高野 歩, ほか:全国の精神科医療施設における薬物関連精神疾患の実態調査. 厚生労働科学研究費補助金(医薬品・医療機器等レギュラトリーサイエンス政策研究事業「危険ドラッグを含む薬物乱用・依存状況の実態把握と薬物依存症者の社会復帰に向けた支援に関する研究」(研究代表者:嶋根卓也)平成28年度 総括・分担研究報告書, p101-136, 国立精神・神経医療研究センター精神保健研究所, 2017.
 
8) 和田 清, 嶋根卓也, 合川勇三, ほか:薬物乱用・依存者におけるHIV感染と行動のモニタリングに関する研究(2017年), 平成29度厚生労働科学研究費補助金(エイズ対策政策研究事業), 2018.
 
9) Jones CM, Olsen EO, O'Donnell J, et al:Resurgent Methamphetamine Use at Treatment Admission in the United States, 2008-2017. Am J Public Health 110:509-516, 2020.
PubMed
10) 田尻 仁, 久保隆彦, 藤沢知雄, ほか:C型肝炎母子感染小児の診療ガイドライン(日本小児栄養消化器肝臓学会, 日本小児感染症学会, 日本肝臓学会, 日本産婦人科学会 編). 日本小児栄養消化器肝臓学会雑誌 34:95-121, 2020.
 
11) Ohto H, Terazawa S, Sasaki N, et al:Transmission of hepatitis C virus from mothers to infants. The vertical transmission of hepatitis C virus collaborative group. N Engl J Med 330:744-750, 1994.
 
12) Grebely J, Page K, Sacks-Davis R, et al:The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infectionw. Hepatology 59:109-120, 2014.
 
13) Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, et al:Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 53:1830-1838, 2011.
PubMed
P.111 掲載の参考文献
1) 樋口 進:物質使用症又は嗜癖行動症群. 精神神経誌 124:877-884, 2022.
 
2) 花ノ木まどか, 加賀谷有行, 古庄立弥, ほか:当院における薬物依存症患者に対するせりがや覚せい剤再使用予防プログラム(SMARPP)の経験. 広島医学 71:527-530, 2018.
 
3) 松本俊彦(研究分担者):令和2年度厚生労働行政推進調査事業費補助金(医薬品・医療機器等レギュラトリーサイエンス政策研究事業)分担報告書 全国の精神科医療施設における薬物関連精神疾患の実態調査, 2021. [https://www.ncnp.go.jp/nimh/yakubutsu/report/pdf/J_NMHS_2020.pdf]
 
4) エドワード・J・カンツィアン, マーク・J・アルバニーズ(著), 松本俊彦(訳):トラウマと自己治療仮説. 人はなぜ依存症になるのか-自己治療としてのアディクション, p93-103, 星和書店, 2013.
 
5) 松本俊彦:物質使用障害とトラウマ. 臨床精神医学 47:799-804, 2018.
Medical*Online
6) 麻薬・覚醒剤行政の概況(2022年12月)(厚生労働省医薬・生活衛生局監視指導・麻薬対策課), 2022.
 
7) 津久江一郎:覚せい剤・有機溶剤中毒に対する救急処置. 精神科 MOOK Vol.20 精神科救急医療(山崎敏雄 編), p185-199, 金原出版, 1988.
 
8) Matsumoto T, Kamijo A, Miyakawa T, et al:Methamphetamine in Japan:the consequences of methamphetamine abuse as a function of route of administration. Addiction 97:809-817, 2002.
PubMed
9) 田中栄司, 山田修平:覚醒剤常用者と HCV 感染. 日本臨牀 53(増刊号 4:分子肝炎ウイルス病学):465-467, 1995.
 
10) 市村 宏, 今西二郎, 栗村 統, ほか:静注薬物常用者における血液媒介性ウィルスの浸淫状況. 臨床とウィルス 23:160-164, 1995.
 
11) Kagaya A, Nagaoki Y, Shimura S, et al:A single site study to investigate the current prevalence of anti-Hepatitis C virus antibody among substance use disorder patients in Hiroshima-Insufficient testing and diagnosis. Neuropsychopharmacol Rep, 2023. (DOI:10.1002/npr2.12346)
 
12) 田中純子, 杉山 文, 加賀谷有行, ほか:厚生労働科学研究費補助金(肝炎等克服政策事業) 令和3年度研究報告書「肝炎ウィルス感染状況の把握及び肝炎ウィルス排除への方策に資する疫学研究」薬物乱用者集団における肝炎ウイルス感染状況に関する血清疫学調査研究. [https://mhlw-grants.niph.go.jp/system/files/report_pdf/202121002A-buntan9.pdf]
 
13) 依存症対策全国センター:薬物使用による健康のリスク-薬物使用に関する健康問題:HIV感染症およびC型肝炎. [https://www.ncasa-japan.jp/understand/drug/risk]
 
14) American Association for the Study of Liver Diseases, Infectious Diseases Society of America, HCV guidance:Recommendations for testing, managing, and treating hepatitis C:Key Populations:Identification and Management of HCV in People Who Inject Drugs. [https://www.hcvguidelines.org/unique-populations/pwid]
 
15) Tamori A, Uchida-Kobayashi S, Kozuka R, et al:High dropout rate from aftercare program of antihepatitis C therapy for patients with history of injection drug use. JGH Open 4:964-969, 2020.
PubMed
16) 松本俊彦:ハームリダクションとは何か?-その理念と意義, わが国での実施. 日本医事新報(5081):18-30, 2021.
Medical*Online
17) SMARPP-24 物質使用障害治療プログラム[改訂版](松本俊彦, 今村扶美, 近藤あゆみ 監), 金剛出版, 2022.
 
P.117 掲載の参考文献
1) Baumert TF, Fauvelle C, Chen DY, et al:A prophylactic hepatitis C virus vaccine:a distant peak still worth climbing. J Hepatol 61:S34-S44, 2014.
PubMed
2) Rosenberg BR, Depla M, Freije CA, et al:Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance. PLoS Pathog 14:e1007290, 2018.
PubMed
3) Yoshio S, Kanto T, Kuroda S, et al:Human blood dendritic cell antigen 3 (BDCA3)+dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Hepatology 57:1705-1715, 2013.
 
4) Wolski D, Foote PK, Chen DY, et al:Early Transcriptional Divergence Marks Virus-Specific Primary Human CD8+ T Cells in Chronic versus Acute Infection. Immunity 47:648-663. e8, 2017.
 
5) Salimi Alizei E, Hofmann M, Thimme R, et al:Mutational escape from cellular immunity in viral hepatitis:variations on a theme. Curr Opin Virol 50:110-118, 2021.
PubMed
6) Cai C, Samir J, Pirozyan MR, et al:Identification of human progenitors of exhausted CD8+ T cells associated with elevated IFN-γ response in early phase of viral infection. Nat Commun 13:7543, 2022.
 
7) Kinchen VJ, Zahid MN, Flyak AI, et al:Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Cell Host Microbe 24:717-730. e5, 2018.
 
8) Nishio A, Hasan S, Park H, et al:Serum neutralization activity declines but memory B cells persist after cure of chronic hepatitis C. Nat Commun 13:5446, 2022.
PubMed
9) Mazouz S, Salinas E, Bedard N, et al:Differential immune transcriptomic profiles between vaccinated and resolved HCV reinfected subjects. PLoS Pathog 18:e1010968, 2022.
PubMed
10) Hlady RA, Zhao X, El Khoury LY, et al:Interferon drives HCV scarring of the epigenome and creates targetable vulnerabilities following viral clearance. Hepatology 75:983-996, 2022.
PubMed
11) Yates KB, Tonnerre P, Martin GE, et al:Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat Immunol 22:1020-1029, 2021.
PubMed
12) Oltmanns C, Liu Z, Mischke J, et al:Reverse inflammaging:Long-term effects of HCV cure on biological age. J Hepatol 78:90-98, 2023.
 
13) Frumento N, Figueroa A, Wang T, et al:Repeated exposure to heterologous hepatitis C viruses associates with enhanced neutralizing antibody breadth and potency. J Clin Invest 132:e160058, 2022.
PubMed
14) Page K, Melia MT, Veenhuis RT, et al:Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection. N Engl J Med 384:541-549, 2021.
PubMed
15) Barnes E, Cooke GS, Lauer GM, et al:Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates. Hepatology 77:1757-1772, 2023.
PubMed
P.120 掲載の参考文献
1) Sakai A, Claire MS, Faulk K, et al:The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci USA 100:11646-11651, 2003.
PubMed
2) Lohmann V, Korner F, Koch J, et al:Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113, 1999.
 
3) De Francesco R, Migliaccio G:Challenges and successes in developing new therapies for hepatitis C. Nature 436:953-960, 2005.
PubMed
4) Gao B, Hong F, Radaeva S:Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology 39:880-890, 2004.
 
5) Shimakami T, Hijikata M, Luo H, et al:Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. J Virol 78:2738-2748, 2004.
 
P.127 掲載の参考文献
1) Cacoub P, Saadoun D:Extrahepatic Manifestations of Chronic HCV Infection. N Engl J Med 384:1038-1052, 2021.
PubMed
2) Calvaruso V, Craxi A:Hepatic benefits of HCV cure. J Hepatol 73:1548-1556, 2020.
 
3) Kiyosawa K, Sodeyama T, Tanaka E, et al:Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma:analysis by detection of antibody to hepatitis C virus. Hepatology 12:671-675, 1990.
PubMed
4) Shiratori Y, Imazeki F, Moriyama M, et al:Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 132:517-524, 2000.
PubMed
5) Poynard T, McHutchison J, Manns M, et al:Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313, 2002.
PubMed
6) Morgan RL, Baack B, Smith BD, et al:Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma:a meta-analysis of observational studies. Ann Intern Med 158:329-337, 2013.
PubMed
7) Reig M, Marino Z, Perello C, et al:Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65:719-726, 2016.
PubMed
8) Alberti A, Piovesan S:Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C:Fact or fiction? Liver Int 37:802-808, 2017.
PubMed
9) Singal AG, Rich NE, Mehta N, et al:Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 156:1683-1692. e1, 2019.
 
10) Ioannou GN, Feld JJ:What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? Gastroenterology 156:446-460. e2, 2019.
 
11) Nagata H, Nakagawa M, Asahina Y, et al:Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67:933-939, 2017.
 
12) Sapena V, Enea M, Torres F, et al:Hepatocellular carcinoma recurrence after direct-acting antiviral therapy:an individual patient data meta-analysis. Gut 71:593-604, 2022.
PubMed
13) Roguljic H, Nincevic V, Bojanic K, et al:Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection:An Update. Front Pharmacol 12:678546, 2021.
PubMed
14) Hashimoto S, Yatsuhashi H, Abiru S, et al:Rapid Increase in Serum Low-Density Lipoprotein Cholesterol Concentration during Hepatitis C Interferon-Free Treatment. PLoS One 11:e0163644, 2016.
PubMed
15) Butt AA, Yan P, Shuaib A, et al:Direct-Acting Antiviral Therapy for HCV Infection Is Associated With a Reduced Risk of Cardiovascular Disease Events. Gastroenterology 156:987-996. e8, 2019.
 
16) Adinolfi LE, Petta S, Fracanzani AL, et al:Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events:A prospective multicentre study. Atherosclerosis 296:40-47, 2020.
PubMed
17) Krassenburg LAP, Maan R, Ramji A, et al:Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 74:1053-1063, 2021.
PubMed
18) D'Ambrosio R, Degasperi E, Anolli MP, et al:Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. J Hepatol 76:302-310, 2022.
PubMed
19) Tahata Y, Hikita H, Mochida S, et al:Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol 57:120-132, 2022.
PubMed
20) Nakagawa M, Asahina Y, Kakinuma S, et al:Impact of eradication of hepatitis C virus on liver-related and-unrelated diseases:morbidity and mortality of chronic hepatitis C after SVR. J Gastroenterol 58:299-310, 2023.
PubMed
21) Nakagawa M, Nawa N, Takeichi E, et al:Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol 55:990-999, 2020.
 
22) Kawagishi N, Suda G, Kimura M, et al:High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. Hepatol Res 50:671-681, 2020.
PubMed
23) Kawagishi N, Suda G, Kimura M, et al:Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. Sci Rep 11:9207, 2021.
PubMed
24) Tahata Y, Sakamori R, Yamada R, et al:Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis. Hepatol Res 52:824-832, 2022.
PubMed
25) Tamaki N, Kurosaki M, Yasui Y, et al:Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. Hepatol Commun 6:461-472, 2022.
PubMed
P.132 掲載の参考文献
1) Teraoka Y, Uchida T, Imamura M, et al:Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochem Biophys Res Commun 500:152-157, 2018.
 
2) Itakura J, Kurosaki M, Hasebe C, et al:Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS One 11:e0165339, 2016.
PubMed
3) Yoshimi S, Imamura M, Murakami E, et al:Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 87:1913-1920, 2015.
PubMed
4) Hikita H, Takehara T:NS5A-P32 Deletion in Hepatitis C Genotype 1b Infection is the Most Refractory Treatment-Mediated Amino Acid Change Exhibiting Resistance to all NS5A Inhibitors. Semin Liver Dis 40:143-153, 2020.
PubMed
5) Krishnan P, Schnell G, Tripathi R, et al:Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother 62:e02217-17, 2018.
PubMed
6) Ng TI, Krishnan P, Pilot-Matias T, et al:In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother 61:e02558-16, 2017.
PubMed
7) Kumada H, Watanabe T, Suzuki F, et al:Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3infection. J Gastroenterol 53:566-575, 2018.
 
8) Osawa M, Imamura M, Teraoka Y, et al:Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 54:291-296, 2019.
PubMed
9) Sezaki H, Suzuki F, Hosaka T, et al:Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections. J Gastroenterol 54:916-927, 2019.
PubMed
10) Uemura H, Uchida Y, Kouyama JI, et al:NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol 54:459-470, 2019.
PubMed
11) Izumi N, Takehara T, Chayama K, et al:Sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 hepatitis C who failed direct-acting antivirals. Hepatol Int 12:356-367, 2018.
PubMed
12) C型肝炎治療ガイドライン(第8.2版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2023.
 
13) Takaki S, Imamura M, Yamaguchi S, et al:Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection. Clin J Gastroenterol 13:1233-1238, 2020.
PubMed
P.137 掲載の参考文献
1) Nakagawa M, Asahina Y, Kakinuma S, et al:Impact of eradication of hepatitis C virus on liver-related and-unrelated diseases:morbidity and mortality of chronic hepatitis C after SVR. J Gastroenterol 58:299-310, 2023.
PubMed
2) Takehara T, Sakamoto N, Nishiguchi S, et al:Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis:an open-label phase 3 trial. J Gastroenterol 54:87-95, 2019.
PubMed
3) European Association for the Study of the Liver; Clinical Practice Guidelines Panel:EASL recommendations on treatment of hepatitis C:Final update of the series. J Hepatol 73:1170-1218, 2020.
 
4) Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel:Hepatitis C Guidance 2019 Update:American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology 71:686-721, 2020.
 
5) Omata M, Kanda T, Wei L, et al:APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int 10:681-701, 2016.
PubMed
6) Tahata Y, Hikita H, Mochida S, et al:Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis:a Japanese real-world multicenter study. J Gastroenterol 56:67-77, 2021.
PubMed
7) El-Sherif O, Jiang ZG, Tapper EB, et al:Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 154:2111-2121. e8, 2018.
 
8) Verna EC, Morelli G, Terrault NA, et al:DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis:Real-world experience from HCV-TARGET cohort. J Hepatol 73:540-548, 2020.
PubMed
9) Sano T, Amano K, Ide T, et al:A combination of hepatic encephalopathy and body mass index was associated with the point of no return for improving liver functional reserve after sofosbuvir/velpatasvir treatment in patients with hepatitis C virus-related decompensated cirrhosis. Hepatol Res 53:26-34, 2023.
PubMed
10) Katoh R, Maekawa S, Osawa L, et al:Significance of serum IP-10/CXCL10 measurement in predicting post-direct acting antiviral treatment liver function in patients with HCV-decompensated liver cirrhosis. Hepatol Res 53:280-288, 2023.
PubMed
11) Tahata Y, Hikita H, Mochida S, et al:Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis. J Gastroenterol 57:120-132, 2022.
PubMed
12) Krassenburg LAP, Maan R, Ramji A, et al:Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. J Hepatol 74:1053-1063, 2021.
PubMed
13) Pageaux GP, Nzinga CL, Ganne N, et al:Clinical outcomes after treatment with direct antiviral agents:beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infect Dis 22:94, 2022.
PubMed
14) Lens S, Baiges A, Alvarado-Tapias E, et al:Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol 73:1415-1424, 2020.
PubMed
15) Tsuji S, Uchida Y, Uemura H, et al:Involvement of portosystemic shunts in impaired improvement of liver function after direct-acting antiviral therapies in cirrhotic patients with hepatitis C virus. Hepatol Res 50:512-523, 2020.
PubMed
16) Kumada T, Toyoda H, Yasuda S, et al:Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus. Infect Dis Ther 10:1001-1013, 2021.
PubMed
P.142 掲載の参考文献
1) Conjeevaram HS, Fried MW, Jeffers LJ, et al:Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131:470-477, 2006.
PubMed
2) Ge D, Fellay J, Thompson AJ, et al:Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401, 2009.
PubMed
3) Suppiah V, Moldovan M, Ahlenstiel G, et al:IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41:1100-1104, 2009.
PubMed
4) Tanaka Y, Nishida N, Sugiyama M, et al:Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105-1109, 2009.
PubMed
5) Thomas DL, Thio CL, Martin MP, et al:Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461:798-801, 2009.
PubMed
6) Hayes CN, Kobayashi M, Akuta N, et al:HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60:261-267, 2011.
PubMed
7) McCarthy JJ, Li JH, Thompson A, et al:Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138:2307-2314, 2010.
 
8) Lindh M, Lagging M, Arnholm B, et al:IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat 18:e325-331, 2011.
PubMed
9) Naggie S, Osinusi A, Katsounas A, et al:Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients:impaired viral kinetics and therapeutic response. Hepatology 56:444-454, 2012.
PubMed
10) Hayes CN, Imamura M, Aikata H, et al:Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol 9:406-417, 2012.
PubMed
11) Prokunina-Olsson L, Muchmore B, Tang W, et al:A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164-171, 2013.
PubMed
12) Fellay J, Thompson AJ, Ge D, et al:ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464:405-408, 2010.
PubMed
13) Ochi H, Maekawa T, Abe H, et al:ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology 139:1190-1197, 2010.
PubMed
14) Hitomi Y, Cirulli ET, Fellay J, et al:Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 140:1314-1321, 2011.
 
15) Nystrom K, Wanrooij PH, Waldenstrom J, et al:Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus. J Virol 92:e01087-18, 2018.
PubMed
P.150 掲載の参考文献
1) Uchida Y, Kouyama JI, Naiki K, et al:"Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline. Hepatol Res 47:1397-1407, 2017.
PubMed
2) Uchida Y, Kouyama JI, Naiki K, et al:Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism. Hepatol Res 46:1234-1246, 2016.
PubMed
3) Krishnan P, Schnell G, Tripathi R, et al:Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother 62:e02217-17, 2018.
PubMed
4) Osawa M, Imamura M, Teraoka Y, et al:Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 54:291-296, 2019.
PubMed
5) Uemura H, Uchida Y, Kouyama JI, et al:NS5A-P32 deletion as a factor involved in virologic failure in patients receiving glecaprevir and pibrentasvir. J Gastroenterol 54:459-470, 2019.
PubMed
6) Kurata H, Uchida Y, Kouyama JI, et al:Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination:A pitfall in antiviral therapy with direct-acting antivirals. Hepatol Res 48:E372-E378, 2018.
PubMed
7) Itakura J, Kurosaki M, Hasebe C, et al:Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure. PLoS One 11:e0165339, 2016.
PubMed
8) Teraoka Y, Uchida T, Imamura M, et al:Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. Biochem Biophys Res Commun 500:152-157, 2018.
 
9) Doi A, Hikita H, Sakamori R, et al:Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection. Hepatology 68:380-383, 2018.
PubMed
10) Penin F, Brass V, Appel N, et al:Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 279:40835-40843, 2004.
PubMed
11) Tellinghuisen TL, Marcotrigiano J, Rice CM:Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374-379, 2005.
PubMed
12) Love RA, Brodsky O, Hickey MJ, et al:Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83:4395-4403, 2009.
 
13) Lambert SM, Langley DR, Garnett JA, et al:The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci 23:723-734, 2014
 
P.156 掲載の参考文献
1) Lombardi A, Colaneri M, Vijayagopal KA, et al:Patients with chronic hepatitis C receiving treatment with direct acting antivirals:How is this population changing? Dig Liver Dis 53:456-460, 2021.
 
2) Ikeda K, Saitoh S, Arase Y, et al:Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C:A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29:1124-1130, 1999.
 
3) Nagata H, Nakagawa M, Asahina Y, et al:Effect of interferon-based and-free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 67:933-939, 2017.
 
4) Asahina Y, Tsuchiya K, Tamaki N, et al:Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 52:518-527, 2010.
PubMed
5) Nakajima T, Karino Y, Hige S, et al:Aging impairs fibrosis-4 index after sustained virologic response by direct-acting antivirals in chronic hepatitis C infection. Ann Hepatol 27:100566, 2022.
PubMed
6) Sicras Mainar A, Navarro Artieda R, Hernandez I, et al:Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. Gastroenterol Hepatol 42:465-475, 2019.
PubMed
7) Huntley M, McCall K, Stickney K, et al:Avoidance of drug interactions with hepatitis C treatment:Evaluation of pharmacist interventions in the specialty setting. J Am Pharm Assoc 62:1671-1674, 2022.
 
8) Margusino-Framinan L, Cid-Silva P, Gimenez-Arufe V, et al:Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. Eur J Hosp Pharm 28:16-21, 2021.
PubMed
9) Simon MA, Rojo O, Ryan P:Patients' preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection. Rev Esp Sanid Penit 23:67-75, 2021.
PubMed
10) Durante-Mangoni E, Parrella A, Vitrone M, et al:Electrophysiological Adverse Effects of Direct Acting Antivirals in Patients With Chronic Hepatitis C. J Clin Pharmacol 57:924-930, 2017.
PubMed
11) Amoros-Reboredo P, Sotoca JM, Marino Z, et al:Efficacy and safety of direct-acting antivirals in older patients with cirrhosis and high comorbidity index. Eur J Gastroenterol Hepatol 32:389-394, 2020.
PubMed
12) CKD診療ガイド 2012(日本腎臓学会 編), 東京医学社, 2012.
 
13) Komaki Y, Ozono Y, Nakamura K, et al:Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older. BMC Gastroenterol 22:210, 2022.
 
14) Huynh T, Hu KQ:Excellent Safety and Sustained Virologic Response to Direct-Acting Antivirals Treatment in HCV-Infected Geriatric Patients:A Real-World Data. Dig Dis Sci 66:1327-1334, 2021.
PubMed
15) Qureshi K, Petersen T, Andres J:Hepatitis C Treatment Differences in Elderly Patients:Single-Center Retrospective Study. Ann Pharmacother 54:113-121, 2020
PubMed
P.162 掲載の参考文献
1) Choo QL, Kuo G, Weiner AJ, et al:Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362, 1989.
 
2) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
3) Kiyosawa K, Sodeyama T, Tanaka E, et al:Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma:analysis by detection of antibody to hepatitis C virus. Hepatology 12:671-675, 1990.
PubMed
4) 日本消化器病学会 肝機能研究班:肝疾患における肝炎ウイルスマーカーの選択基準(4版). 日本消化器学会雑誌 103:1403-1412, 2006.
 
5) 厚生労働省:ウイルス性肝炎患者等の重症化予防推進事業の実施について;(4)肝炎ウイルス検査の結果の判定. 健肝発 0331 第1号, 平成26年3月31日.
 
6) Pereira BJ, Levey AS:Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51:981-999, 1997.
PubMed
7) 出口松夫, 鍵田正智, 山下順香, ほか:HCV抗体スクリーニング検査法の比較. 感染症学雑誌 76:711-720, 2002.
 
8) Aoyagi K, Ohue C, Iida K, et al:Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J Clin Microbiol 37:1802-1808, 1999.
PubMed
P.168 掲載の参考文献
1) 日本超音波医学会 超音波エラストグラフィ診療ガイドライン:肝臓(工藤正俊, 椎名 毅, 森安史典, ほか)[https://www.jsum.or.jp/committee/diagnostic/pdf/elast_kan_ja.pdf]
 
2) Shiina T, Nightingale KR, Palmeri ML, et al:WFUMB guidelines and recommendations for clinical use of ultrasound elastography:Part 1:basic principles and terminology. Ultrasound Med Biol 41:1126-1147, 2015.
PubMed
3) European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado:EASL-ALEH Clinical Practice Guidelines:Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63:237-264, 2015.
 
4) Barr RG, Wilson SR, Rubens D, et al:Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement. Radiology 296:263-274, 2020.
 
5) Cassinotto C, Lapuyade B, Mouries A, et al:Non-invasive assessment of liver fibrosis with impulse elastography:comparison of Supersonic Shear Imaging with ARFI and FibroScan. J Hepatol 61:550-557, 2014.
PubMed
6) Iijima H, Tada T, Kumada T, et al:Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices. Hepatol Res 49:676-686, 2019.
PubMed
7) Broquetas T, Herruzo-Pino P, Marino Z, et al:Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. Liver Int 41:2733-2746, 2021.
PubMed
8) Masuzaki R, Tateishi R, Yoshida H, et al:Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 49:1954-1961, 2009.
PubMed
9) Tada T, Nishimura T, Matono T, et al:Association of liver stiffness and steatosis with hepatocellular carcinoma development in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response. Hepatol Res 51:860-869, 2021.
PubMed
10) Tachi Y, Hirai T, Kojima Y, et al:Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antivirals. JGH Open 1:44-49, 2017.
PubMed
11) Gyotoku Y, Shirahashi R, Suda T, et al:Role of liver stiffness measurements in patients who develop hepatocellular carcinoma after clearance of the hepatitis C virus. J Med Ultrason(2001) 49:253-259, 2022.
PubMed
12) de Franchis R, Bosch J, Garcia-Tsao G, et al:Baveno VII-Renewing consensus in portal hypertension. J Hepatol 76:959-974, 2022.
PubMed
13) Semmler G, Lens S, Meyer EL, et al:Non-invasive tests for clinically significant portal hypertension after HCV cure. J Hepatol 77:1573-1585, 2022.
 
14) 舟山 慧, 本杉宇太郎:MRエラストグラフィによる肝線維化診断. 日本消化器病学会雑誌 117:43-51, 2020.
Medical*Online
15) Venkatesh SK, Yin M, Ehman RL:Magnetic resonance elastography of liver:technique, analysis. and clinical applications. J Magn Reson Imaging 37:544-555, 2013.
PubMed
16) Wagner M, Corcuera-Solano I, Lo G, et al:Technical Failure of MR Elastography Examinations of the Liver:Experience from a Large Single-Center Study. Radiology 284:401-412, 2017.
PubMed
17) Wang J, Glaser KJ, Zhang T, et al:Assessment of advanced hepatic MR elastography methods for susceptibility artifact suppression in clinical patients. J Magn Reson Imaging 47:976-987, 2018.
PubMed
18) Huwart L, Sempoux C, Vicaut E, et al:Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135:32-40, 2008.
PubMed
19) Wang QB, Zhu H, Liu HL, et al:Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis:A meta-analysis. Hepatology 56:239-247, 2012.
PubMed
20) Ozturk A, Olson MC, Samir AR, et al:Liver fibrosis assessment:MR and US elastography. Abdom Radiol (NY) 47:3037-3050, 2022.
 
21) Loomba R, Cui J, Wolfson T, et al:Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD:A Prospective Study. Am J Gastroenterol 111:986-994, 2016.
PubMed
22) Welle CL, Olson MC, Reeder SB, et al:Magnetic Resonance Imaging of Liver Fibrosis, Fat, and Iron. Radiol Clin North Am 60:705-716, 2022.
PubMed
23) Chuaypen N, Chittmittrapap S, Avihingsanon A, et al:Liver fibrosis improvement assessed by magnetic resonance elastography and Mac-2-binding protein glycosylation isomer in patients with hepatitis C virus infection receiving direct-acting antivirals. Hepatol Res 51:528-537, 2021.
PubMed
24) Shi Y, Qi YF, Lan GY, et al:Three-dimensional MR Elastography Depicts Liver Inflammation, Fibrosis, and Portal Hypertension in Chronic Hepatitis B or C. Radiology 301:154-162, 2021.
PubMed
25) Shin SU, Lee JM, Yu MH, et al:Prediction of esophageal varices in patients with cirrhosis:usefulness of three-dimensional MR elastography with echo-planar imaging technique. Radiology 272:143-153, 2014.
PubMed
26) Sun HY, Lee JM, Han JK, et al:Usefulness of MR elastography for predicting esophageal varices in cirrhotic patients. J Magn Reson Imaging 39:559-566, 2014.
PubMed
27) Bohte AE, de Niet A, Jansen L, et al:Non-invasive evaluation of liver fibrosis:a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol 24:638-648, 2014.
 
28) Lefebvre T, Wartelle-Bladou C, Wong P, et al:Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis. Eur Radiol 29:6477-6488, 2019.
PubMed
29) Kennedy P, Wagner M, Castera L, et al:Quantitative Elastography Methods in Liver Disease:Current Evidence and Future Directions. Radiology 286:738-763, 2018.
PubMed
30) Ferraioli G, De Silvestri A, Lissandrin R, et al:Evaluation of Inter-System Variability in Liver Stiffness Measurements. Ultraschall Med 40:64-75, 2019.
PubMed
P.175 掲載の参考文献
1) Khatun M, Ray RB:Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 8:1249, 2019.
PubMed
2) Murawaki Y, Ikuta Y, Koda M, et al:Serum type III procollagen peptide, type IV collagen 7S domain, central triple-helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease:relationship to liver histology. Hepatology 20:780-787, 1994.
PubMed
3) 上野隆登, 鳥村拓司, 犬塚貞孝, ほか:各種肝疾患における血清タイプ III プロコラーゲンNペプチド, ラミニンの変動と肝免疫組織学的検討. 肝臓 30:429-438, 1989.
 
4) Laurent TC, Laurent UB, Fraser JR:Serum hyaluronan as a disease marker. Ann Med 28:241-253, 1996.
PubMed
5) Ikeda H, Nagashima K, Yanase M, et al:Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 285:G880-G886, 2003.
PubMed
6) Watanabe N, Ikeda H, Nakamura K, et al:Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol 41:616-623, 2007.
PubMed
7) Yamazaki T, Joshita S, Umemura T, et al:Association of Serum Autotaxin Levels with Liver Fibrosis in Patients with Chronic Hepatitis C. Sci Rep 7:46705, 2017.
PubMed
8) Kuno A, Ikehara Y, Tanaka Y, et al:A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 3:1065, 2013.
PubMed
9) Yamasaki K, Tateyama M, Abiru S, et al:Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 60:1563-1570, 2014.
PubMed
10) Fujiyoshi M, Kuno A, Gotoh M, et al:Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 50:1134-1144, 2015.
PubMed
11) Nakagawa M, Nawa N, Takeichi E, et al:Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs. J Gastroenterol 55:990-999, 2020.
 
12) Shirabe K, Bekki Y, Gantumur D, et al:Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis:more than a biomarker of liver fibrosis. J Gastroenterol 53:819-826, 2018.
PubMed
13) Houot M, Ngo Y, Munteanu M, et al:Systematic review with meta-analysis:direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Aliment Pharmacol Ther 43:16-29, 2016.
 
14) Martinez SM, Fernandez-Varo G, Gonzalez P, et al:Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 33:138-148, 2011.
PubMed
15) Toyoda H, Kumada T, Tada T, et al:Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection. J Gastroenterol Hepatol 30:1183-1189, 2015.
PubMed
P.181 掲載の参考文献
1) Akiba T, Hora K, Imawari M, et al:2011 Japanese Society for Dialysis Therapy guidelines for the treatment of hepatitis C virus infection in dialysis patients. Ther Apher Dial 16:289-310, 2012.
PubMed
2) Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al:Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 18:1584-1593, 2007.
PubMed
3) Goodkin DA, Bragg-Gresham JL, Koenig KG, et al:Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States:the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14:3270-3277, 2003.
PubMed
4) C型肝炎治療ガイドライン(第8.2版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2023.
 
5) Gane E, Lawitz E, Pugatch D, et al:Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. N Engl J Med 377:1448-1455, 2017.
PubMed
6) Kumada H, Watanabe T, Suzuki F, et al:Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol 53:566-575, 2018.
 
7) Atsukawa M, Tsubota A, Toyoda H, et al:The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment:a prospective, multicenter study. Aliment Pharmacol Ther 49:1230-1241, 2019.
PubMed
P.185 掲載の参考文献
1) Tatsunami S, Mimaya J, Shirahata A, et al:Current status of Japanese HIV-infected patients with coagulation disorders:coinfection with both HIV and HCV. Int J Hematol 88:304-310, 2008.
PubMed
2) Ishikane M, Watanabe K, Tsukada K, et al:Acute hepatitis C in HIV-1 infected Japanese Cohort:single center retrospective cohort study. PLoS One 9:e100517, 2014.
PubMed
3) Foster AL, Gaisa MM, Hijdra RM, et al:Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men. Clin Infect Dis 64:284-288, 2017.
PubMed
4) Chan CP, Uemura H, Kwan TH, et al:Review on the molecular epidemiology of sexually acquired hepatitis C virus infection in the Asia-Pacific region. J Int AIDS Soc 23:e25618, 2020.
PubMed
5) Benhamou Y, Bochet M, Di Martino V, et al:Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30:1054-1058, 1999.
PubMed
6) Sulkowski MS, Moore RD, Mehta SH, et al:Hepatitis C and progression of HIV disease. JAMA 288:199-206, 2002.
PubMed
7) Osinusi A, Townsend K, Kohli A, et al:Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 313:1232-1239, 2015.
PubMed
8) Naggie S, Cooper C, Saag M, et al:Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 373:705-713, 2015.
PubMed
9) Rockstroh JK, Lacombe K, Viani RM, et al:Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1:The EXPEDITION-2 Study. Clin Infect Dis 67:1010-1017, 2018.
PubMed
10) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV, Developed by the HHS Panel on Antiretroviral Guidelines for Adults and Adolescents-A Working Group of the NIH Office of AIDS Research Advisory Council (OARAC), Last Update:March 23, 2023. [https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf]
 
11) Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al:Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450, 2004.
PubMed
12) El-Serag HB, Kanwal F, Richardson P, et al:Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology 64:130-137, 2016.
PubMed
13) Martin TC, Martin NK, Hickman M, et al:Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. AIDS 27:2551-2557, 2013.
PubMed
14) Schmidt AJ, Rockstroh JK, Vogel M, et al:Trouble with bleeding:risk factors for acute hepatitis C among HIV-positive gay men from Germany-a case-control study. PLoS One 6:e17781, 2011.
 
15) Tsukada K, Sugawara Y, Kaneko J, et al:Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs:experience in a single center. Transplantation 91:1261-1264, 2011.
 
P.191 掲載の参考文献
1) Ueda Y, Uemoto S:Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients. Transplantation 100:54-60, 2016.
PubMed
2) Akamatsu N, Sugawara Y, Kokudo N, et al:Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan:results of a nationwide survey. Transpl Int 27:767-774, 2014.
PubMed
3) Ueda Y, Ikegami T, Soyama A, et al:Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation:A Japanese multicenter experience. Hepatol Res 46:1285-1293, 2016.
 
4) Ueda Y, Ikegami T, Akamatsu N, et al:Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation:a Japanese multicenter experience. J Gastroenterol 52:986-991, 2017.
PubMed
5) Ueda Y, Kobayashi T, Ikegami T, et al:Efficacy and safety of glecaprevir and pibrentasvir treatment for 8 or 12 weeks in patients with recurrent hepatitis C after liver transplantation:a Japanese multicenter experience. J Gastroenterol 54:660-666, 2019.
PubMed
6) Takehara T, Sakamoto N, Nishiguchi S, et al:Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis:an open-label phase 3 trial. J Gastroenterol 54:87-95, 2019.
PubMed
7) Tahata Y, Hikita H, Mochida S, et al:Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis:a Japanese real-world multicenter study. J Gastroenterol 56:67-77, 2021.
PubMed
8) Perricone G, Duvoux C, Berenguer M, et al:Delisting HCV-infected liver transplant candidates who improved after viral eradication:Outcome 2 years after delisting. Liver Int 38:2170-2177, 2018.
PubMed
9) Pascasio JM, Vinaixa C, Ferrer MT, et al:Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J Hepatol 67:1168-1176, 2017.
PubMed
10) El-Sherif O, Jiang ZG, Tapper EB, et al:Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. Gastroenterology 154:2111-2121. e8, 2018.
 
11) European Association for the Study of the Liver:EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 69:461-511, 2018.
 
12) Agarwal K, Castells L, Mullhaupt B, et al:Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients. J Hepatol 69:603-607, 2018.
PubMed
13) Ikegami T, Ueda Y, Akamatsu N, et al:Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation:A Japanese multicenter experience. Clin Transplant 31:e13109, 2017.
 
P.196 掲載の参考文献
1) Shiratori Y, Shiina S, Teratani T, et al:Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 138:299-306, 2003.
PubMed
2) Shen YC, Hsu C, Chen LT, et al:Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC):a meta-regression approach. J Hepatol 52:889-894, 2010.
 
3) Kawaoka T, Aikata H, Takaki S, et al:IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. J Viral Hepat 18:e550-560, 2011.
PubMed
4) Jeong SC, Aikata H, Katamura Y, et al:Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 13:5188-5195, 2007.
 
5) Reig M, Marino Z, Perello C, et al:Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 65:719-726, 2016.
PubMed
6) Camma C, Cabibbo G, Craxi A:Direct antiviral agents and risk for HCC early recurrence:Much ado about nothing. J Hepatol 65:861-862, 2016.
PubMed
7) Behairy Bel-S, Sira MM, Zalata KR, et al:Transient elastography compared to liver biopsy and morphometry for predicting fibrosis in pediatric chronic liver disease:Does etiology matter? World J Gastroenterol 22:4238-4249, 2016.
PubMed
8) Petta S, Cabibbo G, Barbara M, et al:Hepatocellular carcinoma recurrence in patients with curative resection or ablation:impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 45:160-168, 2017.
 
9) Ikeda K, Kawamura Y, Kobayashi M, et al:Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 62:2932-2942, 2017.
PubMed
10) Mashiba T, Joko K, Kurosaki M, et al:Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS One 13:e0194704, 2018.
PubMed
11) Nagaoki Y, Imamura M, Nishida Y, et al:The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma:Comparison with interferon-based therapy. J Med Virol 91:650-658, 2019.
PubMed
12) Nishibatake Kinoshita M, Minami T, Tateishi R, et al:Impact of direct-acting antivirals on early recurrence of HCV-related HCC:Comparison with interferon-based therapy. J Hepatol 70:78-86,2019.
PubMed
13) Manthravadi S, Paleti S, Pandya P: Impact of sustained viral response postcurative therapy of hepatitis C-related hepatocellular carcinoma: a systematic review and meta-analysis. Int J Cancer 140: 1042-1049, 2017.
PubMed
14) Waziry R, Hajarizadeh B, Grebely J, et al: Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 67:1204-1212, 2017.
PubMed
15) C型肝炎治療ガイドライン(第8.2版)(日本肝臓学会 肝炎診療ガイドライン作成委員会編), p26-27, 2023.
 
P.202 掲載の参考文献
1) World Health Organization(WHO):Guidelines for the screening, care and treatment of persons with hepatitis C infection, p25, WHO, Geneva, 2016.
 
2) Yatsuhashi H, Yano M:Natural history of chronic hepatitis C. J Gastroenterol Hepatol 15(Suppl):E111-E116, 2000.
 
3) Ueda T, Ohta K, Suzuki N, et al:Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 146:266-268, 1992.
PubMed
4) Nagao Y, Sata M, Suzuki H, et al:Histological improvement of oral Lichen planus in patients with chronic hepatitis C treated with interferon. Gastroenterology 117:283-284, 1999.
PubMed
5) Wagner B, Vierhapper H, Hofmann H:Prevalence of hepatitis C virus infection in Hashimoto's thyroiditis. BMJ 312:640-641, 1996.
PubMed
6) Pawlotsky JM, Ben Yahia M, Andre C, et al:Immunological disorders in C virus chronic active hepatitis:a prospective case-control study. Hepatology 19:841-848, 1994.
 
7) Koike K, Moriya K, Ishibashi K, et al:Sialadenitis histologically resembling Sjogren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA 94:233-236, 1997.
PubMed
8) Yamabe H, Inuma H, Osawa H, et al:Glomerular deposition of hepatitis C virus in membranoproliferative glomerulonephritis. Nephron 72:741, 1996.
PubMed
9) Arase Y, Ikeda K, Tsubota A, et al:Serum levels of gamma-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection. Hepatol Res 25:14-21, 2003.
PubMed
10) Arase Y, Kobayashi M, Suzuki F, et al:Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 57:964-973, 2013.
PubMed
11) Kawamura Y, Ikeda K, Arase Y, et al:Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 120:1034-1041, 2007.
PubMed
12) Arase Y, Suzuki F, Suzuki Y, et al:Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 49:739-744, 2009.
PubMed
13) Arase Y, Suzuki F, Kawamura Y, et al:Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 41:946-954, 2011.
PubMed
14) Arase Y, Suzuki F, Suzuki Y, et al:Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol 82:390-395, 2010.
PubMed
15) Arase Y, Kobayashi M, Kawamura Y, et al:Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. J Med Virol 86:169-175, 2014.
PubMed
P.207 掲載の参考文献
1) Enomoto H, Ueno Y, Hiasa Y, et al:Transition in the etiology of liver cirrhosis in Japan:a nationwide survey. J Gastroenterol 55:353-362, 2020.
PubMed
2) Tateishi R, Uchino K, Fujiwara N, et al:A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan:2011-2015 update. J Gastroenterol 54:367-376, 2019.
PubMed
3) Ikai I, Arii S, Okazaki M, et al:Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 37:676-691, 2007.
PubMed
4) Kudo M, Izumi N, Kokudo N, et al:Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013). Hepatol Res 52:5-66, 2022.
PubMed
5) Tanaka J, Kumagai J, Katayama K, et al:Sex- and age-specific carriers of hepatitis B and C viruses in Japan estimated by the prevalence in the 3,485,648 first-time blood donors during 1995-2000. Intervirology 47:32-40, 2004.
 
6) Tanaka J, Koyama T, Mizui M, et al:Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age-and area-specific prevalence on the national scale. Intervirology 54:185-195, 2011.
 
7) Tanaka J, Akita T, Ko K, et al:Countermeasures against viral hepatitis B and C in Japan:An epidemiological point of view. Hepatol Res 49:990-1002, 2019.
 
8) Tanaka J, Akita T, Ohisa M, et al:Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 25:363-372, 2018.
PubMed
9) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
10) Sato T, Do SH, Asao T, et al:Estimating numbers of persons with persistent hepatitis B virus infection transmitted vertically and horizontally in the birth cohort during 1950-1985 in Japan. Hepatol Res 44:E181-E188, 2014.
 
11) World Health Organization:Global Hepatitis Report, 2017. [https://www.who.int/publications/i/item/9789241565455]
 
12) Sakamoto K, Ito K, Yotsuyanagi H, et al:Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan. J Gastroenterol 57:971-980, 2022.
PubMed
13) Velkov S, Ott JJ, Protzer U, et al:The Global Hepatitis B Virus Genotype Distribution Approximated from Available Genotyping Data. Genes (Basel) 9:495, 2018.
PubMed
P.213 掲載の参考文献
1) Fujisaki S, Yokomaku Y, Shiino T, et al:Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol 49:1017-1024, 2011.
PubMed
2) Ito K, Yotsuyanagi H, Sugiyama M, et al:Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol 31:180-189, 2016.
PubMed
3) Umemura T, Tanaka E, Kiyosawa K, et al:Mortality secondary to fulminant hepatic failure inpatients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-56, 2008.
 
4) Aritomi T, Yatsuhashi H, Fujino T, et al:Association of mutations in the core promoter and precore region of hepatitis virus with fulminant and severe acute hepatitis in Japan. J Gastroenterol Hepatol 13:1125-1132, 1998.
PubMed
5) Sugauchi F, Orito E, Ohno T, et al:Spatial and chronological differences in hepatitis B virus genotypes from patients with acute hepatitis B in Japan. Hepatol Res 36:107-114, 2006.
PubMed
6) Terrault NA, Lok ASF, McMahon BJ, et al:Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance. Hepatology 67:1560-1599, 2018.
PubMed
7) European Association for the Study of the Liver:EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67:370-398, 2017.
 
P.217 掲載の参考文献
1) Moriya T, Koyama T, Tanaka J, et al:Epidemiology of hepatitis C virus in japan. Intervirology 42:153-158, 1999.
PubMed
2) Sato T, Do SH, Asao T, et al:Estimating numbers of persons with persistent hepatitis B virus infection transmitted vertically and horizontally in the birth cohort during 1950-1985 in Japan. Hepatol Res 44:E181-E188, 2014.
 
3) Tanaka J, Akita T, Ko K, et al:Countermeasures against viral hepatitis B and C in Japan:An epidemiological point of view. Hepatol Res 49:990-1002, 2019.
 
4) Centers for Disease Control and Prevention (CDC):Progress in hepatitis B prevention through universal infant vaccination-China, 1997-2006. MMWR Morb Mortal Wkly Rep 56:441-445, 2007.
PubMed
5) Shiraki K:Perinatal transmission of hepatitis B virus and its prevention. J Gastroenterol Hepatol 15:E11-E15, 2000.
PubMed
6) Norder H, Courouce AM, Coursaget P, et al:Genetic diversity of hepatitis B virus strains derived worldwide:genotypes, subgenotypes, and HBsAg subtypes. Intervirology 47:289-309, 2004.
PubMed
7) Kurbanov F, Tanaka Y, Mizokami M:Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 40:14-30, 2010.
PubMed
8) Ito K, Yotsuyanagi H, Sugiyama M, et al:Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol 31:180-189, 2016.
PubMed
9) Ito K, Yotsuyanagi H, Yatsuhashi H, et al:Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 59:89-97, 2014.
PubMed
10) Sakamoto K, Ito K, Yotsuyanagi H, et al:Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan. J Gastroenterol 57:971-980, 2022.
PubMed
11) Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the Global Health Sector Strategies 2016-2021:Actions for Impact. World Health Organization, Geneva, 2021.
 
12) Tanaka J, Akita T, Ohisa M, et al:Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat 25:363-372, 2018.
PubMed
13) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
P.222 掲載の参考文献
1) 劇症肝炎の診断基準. A型肝炎, 劇症肝炎:第12回犬山シンポジウム, p110-230, 中外医学社, 1982.
 
2) Sato S, Suzuki K, Takikawa Y, et al:Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation:An analysis of 1,309 cases in a 15-year national survey. Hepatology Res 30:155-161, 2004.
 
3) Fujiwara K, Mochida S, Matsui A, et al:Fulminant hepatitis and late onset hepatic failure in Japan. Hepatology Res 38:646-657, 2008.
PubMed
4) Oketani M, Ido A, Nakayama N, et al:Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan:Summary of the annual nationwide survey between 2004 and 2009. Hepatol Res 43:97-105, 2013.
PubMed
5) Polson J, Lee WM; American Association for the Study of Liver Disease:AASLD position paper:the management of acute liver failure. Hepatology 41:1179-1197, 2005.
 
6) 持田 智, 滝川康裕, 中山伸朗, ほか:我が国における「急性肝不全」の概念, 診断基準の確立:厚生労働省科学研究費補助金(難治性疾患克服研究事業)「難治性の肝・胆道疾患に関する調査研究」班, ワーキンググループ-1, 研究報告. 肝臓 52:393-398, 2011.
 
7) Mochida S, Takikawa Y, Nakayama N, et al:Diagnostic criteria of acute liver failure:A report by the Intractable Hepato-Biliary Diseases Study Group of Japan. Hepatol Res 41:805-812, 2011.
 
8) Sugawara K, Nakayama N, Mochida S:Acute liver failure in Japan:definition, classification, and prediction of the outcome. J Gastroenterol 47:849-861, 2012.
PubMed
9) Mochida S, Nakao M, Nakayama N, et al:Nationwide prospective and retrospective surveys for hepatitis B virus reactivation during immunosuppressive therapies. J Gastroenterol 51:999-1010, 2016.
PubMed
10) Mochida S, Nakayama N, Ido A, et al:Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan:A report by the Intractable Hepato-Biliary Diseases Study Group of Japan in 2015. Hapatol Res 46:369-371, 2016.
 
11) Nakao M, Nakayama N, Uchida Y, et al:Nationwide survey for acute liver failure and late-onset hepatic failure in Japan. J Gastroenterol 53:752-769, 2018
PubMed
12) Oketani M, Ido A, Uto H, et al:Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42:627-636, 2012.
PubMed
13) 坪内博仁, 熊田博光, 清澤研道, ほか:免疫抑制・化学療法により発症するB型肝炎対策-厚生労働省「難治性の肝・胆道疾患に関する調査研究」班劇症肝炎分科会および「肝硬変を含めたウイルス性肝疾患の治療標準化に関する研究」班合同報告. 肝臓 50:38-42, 2009.
 
P.228 掲載の参考文献
1) Kaito M, Ohba H, Chiba J, et al:The ultrastructural morphology of native hepatitis B virus. Med Mol Morphol 39:136-145, 2006.
PubMed
2) Yan H, Zhong G, Xu G, et al:Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 1:e00049, 2012.
 
3) Guo H, Jiang D, Zhou T, et al:Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus:an intermediate of covalently closed circular DNA formation. J Virol 81:12472-12484, 2007
PubMed
4) Lucifora J, Arzberger S, Durantel D, et al:Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 55:996-1003, 2011.
PubMed
5) Belloni L, Pollicino T, De Nicola F, et al:Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 106:19975-19979, 2009.
PubMed
6) Tsukiyama-Kohara K, Kohara M:Tupaia belangeri as an experimental animal model for viral infection. Exp Anim 63:367-374, 2014.
PubMed
P.234 掲載の参考文献
1) Marchetti AL, Guo H:New Insights on Molecular Mechanism of Hepatitis B Virus Covalently Closed Circular DNA Formation. Cells 9:2430, 2020.
PubMed
2) Kostyusheva A, Brezgin S, Glebe D, et al:Host-cell interactions in HBV infection and pathogenesis:the emerging role of m6A modification. Emerg Microbes Infect 10:2264-2275, 2021.
PubMed
3) Wei L, Ploss A:Mechanism of Hepatitis B Virus cccDNA Formation. Viruses 13:1463, 2021.
PubMed
4) Gao W, Hu J:Formation of hepatitis B virus covalently closed circular DNA:removal of genome-linked protein. J Virol 81:6164-6174, 2007.
 
5) Guo H, Jiang D, Zhou T, et al:Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus:an intermediate of covalently closed circular DNA formation. J Virol 81:12472-12484, 2007.
PubMed
6) Luo J, Cui X, Gao L, et al:Identification of an Intermediate in Hepatitis B Virus Covalently Closed Circular (CCC) DNA Formation and Sensitive and Selective CCC DNA Detection. J Virol 91:e00539-17, 2017.
PubMed
7) Koumbi L, Karayiannis P:The Epigenetic Control of Hepatitis B Virus Modulates the Outcome of Infection. Front Microbiol 6:1491, 2016.
PubMed
8) Slagle BL, Bouchard MJ:Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol 30:32-38, 2018.
PubMed
9) Decorsiere A, Mueller H, van Breugel PC, et al:Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 531:386-389, 2016.
PubMed
10) Sunbul M:Hepatitis B virus genotypes:global distribution and clinical importance. World J Gastroenterol 20:5427-5434, 2014.
PubMed
11) Suzuki Y, Kobayashi M, Ikeda K, et al:Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 76:33-39, 2005.
PubMed
12) Wang L, Zou ZQ, Wang K:Clinical Relevance of HLA Gene Variants in HBV Infection. J Immunol Res 2016:9069375, 2016.
PubMed
13) Frodsham AJ, Zhang L, Dumpis U, et al:Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A 103:9148-9153, 2006.
 
14) Rehermann B, Lau D, Hoofnagle JH, et al:Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 97:1655-1665, 1996.
PubMed
P.239 掲載の参考文献
1) Yoshio S, Mano Y, Doi H, et al:Cytokine and chemokine signatures associated with hepatitis B surface antigen loss in hepatitis B patients. JCI Insight 3:e122268, 2018.
PubMed
2) Cheng X, Uchida T, Xia Y, et al:Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest 130:3205-3220, 2020.
PubMed
3) Yoshio S, Sugiyama M, Shoji H, et al:Indoleamine-2, 3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B. Hepatology 63:83-94, 2016.
 
4) Fisicaro P, Valdatta C, Boni C, et al:Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 58:974-982, 2009.
PubMed
5) Publicover J, Gaggar A, Nishimura S, et al:Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 123:3728-3739, 2013.
PubMed
6) Chou HH, Chien WH, Wu LL, et al:Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Natl Acad Sci USA 112:2175-2180, 2015.
PubMed
7) Guidotti LG, Inverso D, Sironi L, et al:Immunosurveillance of the liver by intravascular effector CD8(+) T cells. Cell 161:486-500, 2015.
PubMed
8) Garcia-Lopez M, Lens S, Pallett LJ, et al:Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol 74:1064-1074, 2021.
PubMed
9) Benechet AP, De Simone G, Di Lucia P, et al:Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 574:200-205, 2019.
PubMed
10) Wang H, Luo H, Wan X, et al:TNF-α/IFN-γ profile of HBV-specific CD4 T cells is associated with liver damage and viral clearance in chronic HBV infection. J Hepatol 72:45-56, 2020.
 
11) Yoshikawa S, Yoshio S, Yoshida Y, et al:Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients. J Infect Dis 223:2080-2089, 2021.
PubMed
12) Doi H, Yoshio S, Yoneyama K, et al:Immune Determinants in the Acquisition and Maintenance of Antibody to Hepatitis B Surface Antigen in Adults After First-Time Hepatitis B Vaccination. Hepatol Commun 3:812-824, 2019.
PubMed
13) Salimzadeh L, Le Bert N, Dutertre CA, et al:PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest 128:4573-4587, 2018.
PubMed
14) Le Bert N, Salimzadeh L, Gill US, et al:Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J Hepatol 72:34-44, 2020.
PubMed
15) Xu H, Locarnini S, Wong D, et al:Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol 76:34-45, 2022.
 
P.245 掲載の参考文献
1) Trepo C, Chan HL, Lok A:Hepatitis B virus infection. Lancet 384:2053-2063, 2014.
PubMed
2) 村田一素:B型肝炎ウイルス感染における宿主免疫応答の重要性-特にNKT細胞の関与について-. 肝臓 54:7-18, 2013.
 
3) Guidotti LG, Rochford R, Chung J, et al:Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825-829, 1999.
PubMed
4) Moriyama T, Guilhot S, Klopchin K, et al:Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science 248:361-364, 1990.
PubMed
5) Ando K, Guidotti LG, Wirth S, et al:Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol 152:3245-3253, 1994.
 
6) Murphy KM, Weaver C, Berg LJ:T cell-mediated cytotoxicity. In:Janeway's Immunobiology(ed by Twitchell B, Bressack CB), p394-404, W. W. Norton & Company Inc, New York, 2022.
 
7) Kagi D, Vignaux F, Ledermann B, et al:Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530, 1994.
PubMed
8) Mochizuki K, Hayashi N, Hiramatsu N, et al:Fas antigen expression in liver tissues of patients with chronic hepatitis B. J Hepatol 24:1-7, 1996.
PubMed
9) Galle PR, Hofmann WJ, Walczak H, et al:Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223-1230, 1995.
PubMed
10) Murphy KM, Weaver C, Berg LJ:Consequences of innate immune activation. In:Janeway's Immunobiology (ed by Twitchell B and Bressack CB), p109-140, W. W. Norton & Company Inc, NewYork, 2022.
 
P.251 掲載の参考文献
1) Heermann KH, Goldmann U, Schwartz W, et al:Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 52:396-402, 1984.
 
2) Yan H, Zhong G, Xu G, et al:Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. ELife 1:e00049, 2012.
 
3) Iwamoto M, Saso W, Sugiyama R, et al:Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci USA 116:8487-8492, 2019.
PubMed
4) Urban S, Bartenschlager R, Kubitz R, et al:Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 147:48-64, 2014.
PubMed
5) Fukano K, Tsukuda S, Watashi K, et al:Concept of Viral Inhibitors via NTCP. Semin Liver Dis 39:78-85, 2019.
PubMed
6) Tsukuda S, et al:NTCP. In:Encyclopedia of Signaling Molecules, 2nd ed(ed by Choi S), p3591-3599, Springer, 2017.
 
7) Hu NJ, Iwata S, Cameron AD, et al:Crystal structure of a bacterial homologue of the bile acid sodium symporter ASBT. Nature 478:408-411, 2011.
PubMed
8) Zhou X, Levin EJ, Pan Y, et al:Structural basis of the alternating-access mechanism in a bile acid transporter. Nature 505:569-573, 2014.
 
9) Takeuchi JS, Fukano K, Iwamoto M, et al:A Single adaptive mutation in sodium taurocholate cotransporting polypeptide induced by hepadnaviruses determines virus species specificity. J Virol 93:e01432-18, 2019.
 
10) Yan H, Peng B, He W, et al:Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 87:7977-7991, 2013.
 
11) Peng L, Zhao Q, Li Q, et al:The p. Ser267Phe variant in SLC10A1 is associated with resistance to chronic hepatitis B. Hepatology 61:1251-1260, 2015.
 
12) Park JH, Iwamoto M, Yun JH, et al:Structural insights into the HBV receptor and bile acid transporter NTCP. Nature 606:1027-1031, 2022.
PubMed
13) Asami J, Kimura KT, Fujita-Fujiharu Y, et al:Structure of the bile acid transporter and HBV receptor NTCP. Nature 606:1021-1026, 2022.
PubMed
14) Goutam K, Ielasi FS, Pardon E, et al:Structural basis of sodium-dependent bile salt uptake into the liver. Nature 606:1015-1020, 2022.
PubMed
15) Liu H, Irobalieva RN, Bang-Sorensen R, et al:Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver. Cell Res 32:773-776, 2022.
PubMed
P.258 掲載の参考文献
1) WHO:Hepatitis B. WHO Fact sheets, 2022. [https://www.who.int/news-room/fact-sheets/detail/hepatitis-b]
 
2) Miyakawa Y, Mizokami M:Classifying hepatitis B virus genotypes. Intervirology 46:329-338, 2003.
PubMed
3) Mizokami M, Nakano T, Orito E, et al:Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett 450:66-71, 1999.
PubMed
4) Kato H, Fujiwara K, Gish RG, et al:Classifying genotype F of hepatitis B virus into F1 and F2 subtypes. World J Gastroenterol 11:6295-6304, 2005.
PubMed
5) Okamoto H, Tsuda F, Sakugawa H, et al:Typing hepatitis B virus by homology in nucleotide sequence:comparison of surface antigen subtypes. J Gen Virol 69 (Pt 10):2575-2583, 1988.
 
6) Kao JH, Chen PJ, Lai MY, et al:Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 124:327-334, 2003.
PubMed
7) 溝上雅史(研究代表者):B型肝炎ジェノタイプ A型感染の慢性化など本邦における実態とその予防に関する研究:平成22年度総括・分担研究報告書(厚生労働科学研究費補助金肝炎等克服緊急対策研究事業(肝炎分野)), 2011.
 
8) Sako A, Yasunaga H, Horiguchi H, et al:Acute hepatitis B in Japan:Incidence, clinical practices and health policy. Hepatol Res 41:39-45, 2011.
PubMed
9) Orito E, Ichida T, Sakugawa H, et al:Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
10) Suzuki Y, Kobayashi M, Ikeda K, et al:Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan. J Med Virol 76:33-39, 2005.
PubMed
11) Sakamoto K, Ito K, Yotsuyanagi H, et al:Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan. J Gastroenterol 57:971-980, 2022.
PubMed
12) Sugiyama M, Tanaka Y, Kato T, et al:Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44:915-924, 2006.
PubMed
13) Sugiyama M, Tanaka Y, Kurbanov F, et al:Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes. Gastroenterology 136:652-62. e3, 2009.
 
14) Maslac O, Wagner J, Sozzi V, et al:Secreted hepatitis B virus splice variants differ by HBV genotype and across phases of chronic hepatitis B infection. J Viral Hepat 29:604-615, 2022.
PubMed
15) Lim CS, Sozzi V, Littlejohn M, et al:Quantitative analysis of the splice variants expressed by the major hepatitis B virus genotypes. Microb Genom 7:mgen000492, 2021.
PubMed
16) Gunther S, Sommer G, Iwanska A, et al:Heterogeneity and common features of defective hepatitis B virus genomes derived from spliced pregenomic RNA. Virology 238:363-371, 1997.
PubMed
17) Chu YJ, Yang HI, Hu HH, et al:HBV genotype-dependent association of HLA variants with the serodecline of HBsAg in chronic hepatitis B patients. Sci Rep 13:359, 2023.
PubMed
18) Tanaka Y, Hasegawa I, Kato K, et al:A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 40:747-755, 2004.
 
19) Guarnieri M, Kim KH, Bang G, et al:Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol 80:587-595, 2006.
PubMed
20) Ozasa A, Tanaka Y, Orito E, et al:Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection. Hepatology 44:326-334, 2006.
PubMed
21) Elkady A, Tanaka Y, Kurbanov F, et al:Virological and clinical implication of core promoter C1752/V1753 and T1764/G1766 mutations in hepatitis B virus genotype D infection in Mongolia. J Gastroenterol Hepatol 23:474-481, 2008.
PubMed
P.265 掲載の参考文献
1) Sartorius K, Swadling L, An P, et al:The Multiple Roles of Hepatitis B Virus X Protein (HBx)Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways. Viruses 12:746, 2020.
PubMed
2) Gao W, Jia Z, Tian Y, et al:HBx Protein Contributes to Liver Carcinogenesis by H3K4me3 Modification Through Stabilizing WD Repeat Domain 5 Protein. Hepatology 71:1678-1695, 2020.
PubMed
3) Decorsiere A, Mueller H, van Breugel PC, et al:Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 531:386-389, 2016.
PubMed
4) Ren L, Zeng M, Tang Z, et al:The Antiresection Activity of the X Protein Encoded by Hepatitis Virus B. Hepatology 69:2546-2561, 2019.
PubMed
5) Idrissi ME, Hachem H, Koering C, et al:HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype. J Viral Hepat 23:130-138, 2016.
PubMed
6) Zhou X, Yang F, Yang Y, et al:HBV Facilitated Hepatocellular Carcinoma Cells Proliferation by Up-Regulating Angiogenin Expression Through IL-6. Cell Physiol Biochem 46:461-470, 2018.
 
7) Lau CC, Sun T, Ching AK, et al:Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 25:335-349, 2014.
PubMed
8) Zhao LH, Liu X, Yan HX, et al:Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun 7:12992, 2016.
 
9) Liu Z, Dai X, Wang T, et al:Hepatitis B virus PreS1 facilitates hepatocellular carcinoma development by promoting appearance and self-renewal of liver cancer stem cells. Cancer Lett 400:149-160, 2017.
PubMed
10) Anfuso B, El-Khobar KE, Ie SI, et al:Activation of hepatic stem cells compartment during hepatocarcinogenesis in a HBsAg HBV-transgenic mouse model. Sci Rep 8:13168, 2018.
 
11) Song J, Zhang X, Ge Q, et al:CRISPR/Cas9-mediated knockout of HBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem 119:8419-8431, 2018.
 
12) Podlaha O, Gane E, Brunetto M, et al:Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Sci Rep 9:10529, 2019.
PubMed
13) Tseng TC, Liu CJ, Hsu CY, et al:High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load. Gastroenterology 157:1518-1529. e3, 2019.
 
14) Hosaka T, Suzuki F, Kobayashi M, et al:Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther 49:457-471, 2019.
PubMed
15) Suzuki F, Hosaka T, Imaizumi M, et al:Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Hepatol Res 51:426-435, 2021.
PubMed
P.270 掲載の参考文献
1) Dandri M, Burda MR, Torok E, et al:Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33:981-988, 2001.
PubMed
2) Mercer DF, Schiller DE, Elliott JF, et al:Hepatitis C virus replication in mice with chimeric human livers. Nat Med 7:927-933, 2001.
PubMed
3) Sugahara G, Ishida Y, Sun J, et al:Art of Making Artificial Liver:Depicting Human Liver Biology and Diseases in Mice. Semin Liver Dis 40:189-212, 2020.
PubMed
4) Tateno C, Yoshizane Y, Saito N, et al:Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 165:901-912, 2004.
PubMed
5) Tateno C, Kawase Y, Tobita Y, et al:Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice. PLoS One 10:e0142145, 2015.
 
6) Tabuchi A, Tanaka J, Katayama K, et al:Titration of hepatitis B virus infectivity in the sera of pre-acute and late acute phases of HBV infection:transmission experiments to chimeric mice with human liver repopulated hepatocytes. J Med Virol 80:2064-2068, 2008.
PubMed
7) Komatsu H, Inui A, Sogo T, et al:Tears from children with chronic hepatitis B virus (HBV) infection are infectious vehicles of HBV transmission:experimental transmission of HBV by tears, using mice with chimeric human livers. J Infect Dis 206:478-485, 2012.
PubMed
8) Ishida Y, Chung TL, Imamura M, et al:Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology 68:473-484, 2018.
PubMed
9) Furuta M, Tanaka H, Shiraishi Y, et al:Correction:Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers. Oncotarget 9:31789, 2018.
PubMed
10) Okazaki A, Hiraga N, Imamura M, et al:Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology 56:555-566, 2012.
PubMed
11) Yamasaki C, Kataoka M, Kato Y, et al:In vitro evaluation of cytochrome P450 and glucuronidation activities in hepatocytes isolated from liver-humanized mice. Drug Metab Pharmacokinet 25:539-550, 2010.
PubMed
12) Yamasaki C, Ishida Y, Yanagi A, et al:Culture density contributes to hepatic functions of fresh human hepatocytes isolated from chimeric mice with humanized livers:Novel, long-term, functional two-dimensional in vitro tool for developing new drugs. PLoS One 15:e0237809, 2020.
PubMed
13) Ishida Y, Yamasaki C, Yanagi A, et al:Novel robust in vitro hepatitis B virus infection model using fresh human hepatocytes isolated from humanized mice. Am J Pathol 185:1275-1285, 2015.
PubMed
14) Zhang M, Zhang Z, Imamura M, et al:Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. J Hepatol 75:1335-1345, 2021.
 
P.275 掲載の参考文献
1) Isogawa M, Tanaka Y:Immunobiology of hepatitis B virus infection. Hepatol Res 45:179-189, 2015.
PubMed
2) Suslov A, Boldanova T, Wang X, et al:Hepatitis B Virus Does Not Interfere With Innate Immune Responses in the Human Liver. Gastroenterology 154:1778-1790, 2018.
PubMed
3) Dunn C, Brunetto M, Reynolds G, et al:Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 204:667-680, 2007.
PubMed
4) Maini MK, Boni C, Lee CK, et al:The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269-1280, 2000.
PubMed
5) Asabe S, Wieland SF, Chattopadhyay PK, et al:The size of the viral inoculum contributes to the outcome of hepatitis B virus infection. J Virol 83:9652-9662, 2009.
 
6) Doi H, Yoshio S, Yoneyama K, et al:Immune Determinants in the Acquisition and Maintenance of Antibody to Hepatitis B Surface Antigen in Adults After First-Time Hepatitis B Vaccination. Hepatol Commun 3:812-824, 2019.
PubMed
7) Salimzadeh L, Le Bert N, Dutertre CA, et al:PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest 128:4573-4587, 2018.
PubMed
8) Baudi I, Kawashima K, Isogawa M:HBV-Specific CD8+ T-Cell Tolerance in the Liver. Front Immunol 12:721975, 2021.
PubMed
9) Burton AR, Pallett LJ, McCoy LE, et al:Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest 128:4588-4603, 2018.
PubMed
10) Isogawa M, Chung J, Murata Y, et al:CD40 Activation Rescues Antiviral CD8+ T Cells from PD-1-Mediated Exhaustion. PLoS Pathog 9:e1003490, 2013.
PubMed
11) Kawashima K, Isogawa M, Onishi M, et al:Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation. JCI Insight 6:e145761, 2021.
PubMed
12) Benechet AP, De Simone G, Di Lucia P, et al:Dynamics and genomic landscape of CD8+ T cells undergoing hepatic priming. Nature 574:200-205, 2019.
PubMed
13) Fisicaro P, Barili V, Montanini B, et al:Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B. Nat Med 23:327-336, 2017.
PubMed
14) Acerbi G, Montali I, Ferrigno GD, et al:Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. J Hepatol 74:783-793, 2021.
PubMed
15) Kennedy PTF, Sandalova E, Jo J, et al:Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143:637-645, 2012.
 
P.280 掲載の参考文献
1) Brechot C, Pourcel C, Louise A, et al:Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 286:533-535, 1980.
PubMed
2) Edman JC, Gray P, Valenzuela P, et al:Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 286:535-538, 1980.
 
3) Tu T, Budzinska MA, Shackel NA, et al:HBV DNA Integration:Molecular Mechanisms and Clinical Implications. Viruses 9:75, 2017.
PubMed
4) Sung WK, Zheng H, Li S, et al:Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 44:765-769, 2012.
 
5) Zhao LH, Liu X, Yan HX, et al:Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun 7:12992, 2016.
 
6) Kimbi GC, Kramvis A, Kew MC:Integration of hepatitis B virus DNA into chromosomal DNA during acute hepatitis B. World J Gastroenterol 11:6416-6421, 2005.
PubMed
7) Summers J, Jilbert AR, Yang W, et al:Hepatocyte turnover during resolution of a transient hepadnaviral infection. Proc Natl Acad Sci USA 100:11652-11659, 2003.
PubMed
8) Furuta M, Tanaka H, Shiraishi Y, et al:Characterization of HBV integration patterns and timing in liver cancer and HBV-infected livers. Oncotarget 9:25075-25088, 2018.
PubMed
9) Budzinska MA, Shackel NA, Urban S, et al:Cellular Genomic Sites of Hepatitis B Virus DNA Integration. Genes (Basel) 9:365, 2018.
PubMed
10) Salpini R, D'Anna S, Benedetti L, et al:Hepatitis B virus DNA integration as a novel biomarker of hepatitis B virus-mediated pathogenetic properties and a barrier to the current strategies for hepatitis B virus cure. Front Microbiol 13:972687, 2022.
 
11) Totoki Y, Tatsuno K, Covington KR, et al:Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46:1267-1273, 2014.
PubMed
12) Alvarez EG, Demeulemeester J, Otero P, et al:Aberrant integration of Hepatitis B virus DNA promotes major restructuring of human hepatocellular carcinoma genome architecture. Nat Commun 12:6910, 2021.
PubMed
13) Lau CC, Sun T, Ching AK, et al:Viral-human chimeric transcript predisposes risk to liver cancer development and progression. Cancer Cell 25:335-349, 2014.
PubMed
14) Cao Q, Imbeaud S, Datta S, et al:Authors' response:virus-host interactions in HBV-related hepatocellular carcinoma:more to be revealed? Gut 64:853-854, 2015.
PubMed
15) Muroyama R, Nakagawa R, Matsubara Y, et al:Fusion HBx from HBV integrant affects hepatocarcinogenesis through deregulation of ER stress response. Virus Res 315:198787, 2022.
PubMed
P.286 掲載の参考文献
1) Qiao L, Wu Q, Lu X, et al:SREBP-1a activation by HBx and the effect on hepatitis B virus enhancer II/core promoter. Biochem Biophys Res Commun 432:643-649, 2013.
PubMed
2) Zhang Z, Torii N, Hu Z, et al:X-deficient woodchuck hepatitis virus mutants behave like attenuated viruses and induce protective immunity in vivo. J Clin Invest 108:1523-1531, 2001.
 
3) Yuan H, Zhao L, Yuan Y, et al:HBx represses WDR77 to enhance HBV replication by DDB1-mediated WDR77 degradation in the liver. Theranostics 11:8362-8378, 2021.
 
4) Benhenda S, Ducroux A, Riviere L, et al:Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol 87:4360-4371, 2013.
 
5) Minor MM, Hollinger FB, McNees AL, et al:Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex. Cells 9:834, 2020.
PubMed
6) Murphy CM, Xu Y, Li F, et al:Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. Cell Rep 16:2846-2854, 2016.
 
7) Decorsiere A, Mueller H, van Breugel PC, et al:Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature 531:386-389, 2016.
PubMed
8) Sekiba K, Otsuka M, Ohno M, et al:Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction. Cell Mol Gastroenterol Hepatol 7:297-312, 2019.
PubMed
9) Rossignol JF, Brechot C:A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B. Hepatol Commun 3:744-747, 2019.
PubMed
10) Sekiba K, Otsuka M, Ohno M, et al:Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus. Hepatology 69:1903-1915, 2019.
PubMed
11) Sekiba K, Otsuka M, Funato K, et al:HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. J Hepatol 76:53-62, 2022.
 
P.292 掲載の参考文献
1) Dusheiko G, Agarwal K, Maini MK:New Approaches to Chronic Hepatitis B. N Engl J Med 388:55-69, 2023.
PubMed
2) Fanning GC, Zoulim F, Hou J, et al:Therapeutic strategies for hepatitis B virus infection:towards a cure. Nat Rev Drug Discov 18:827-844, 2019.
PubMed
3) Yoshio S, Kanto T:Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol 51:409-420, 2016.
PubMed
4) Thimme R, Wieland S, Steiger C, et al:CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68-76, 2003.
PubMed
5) Baudi I, Kawashima K, Isogawa M:HBV-Specific CD8+ T-Cell Tolerance in the Liver. Front Immunol 12:721975, 2021.
PubMed
6) Maini MK, Burton AR:Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol 16:662-675, 2019.
PubMed
7) Nakamoto Y, Kaneko S, Fan H, et al:Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 196:1105-1111, 2002.
PubMed
8) Nakamoto Y, Suda T, Momoi T, et al:Different procarcinogenic potentials of lymphocyte subsets in a transgenic mouse model of chronic hepatitis B. Cancer Res 64:3326-3333, 2004.
 
9) Nosaka T, Naito T, Hiramatsu K, et al:Gene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B. PLoS One 12:e0185442, 2017.
 
10) Lucifora J, Xia Y, Reisinger F, et al:Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221-1228, 2014.
PubMed
11) Pasquetto V, Wieland SF, Uprichard SL, et al:Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 76:5646-5653, 2002.
PubMed
12) Nosaka T, Naito T, Matsuda H, et al:Molecular signature of hepatitis B virus regulation by interferon-γ in primary human hepatocytes. Hepatol Res 50:292-302, 2020.
 
13) Nosaka T, Naito T, Murata Y, et al:Regulatory function of interferon-inducible 44-like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes. Hepatol Res 52:141-152, 2022.
PubMed
14) Gane E, Verdon DJ, Brooks AE, et al:Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B:A pilot study. J Hepatol 71:900-907, 2019.
PubMed
15) Rossi M, Vecchi A, Tiezzi C, et al:Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro. Gut, 2023. (DOI:10. 1136/gutjnl-2022-327202)
 
P.296 掲載の参考文献
1) Hirt B:Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 26:365-369, 1967.
PubMed
2) Cai D, Nie H, Yan R, et al:A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol 1030:151-161, 2013.
 
3) Qu B, Ni Y, Lempp FA, et al:T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR. J Virol 92:e01117-18, 2018.
PubMed
4) Werle-Lapostolle B, Bowden S, Locarnini S, et al:Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750-1758, 2004.
PubMed
5) Zhang X, Lu W, Zheng Y, et al:In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J Clin Invest 126:1079-1092, 2016.
 
6) Schiffer JT, Swan DA, Stone D, et al:Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes:a mathematical modeling approach. PLoS Comput Biol 9:e1003131, 2013.
PubMed
7) Lin SR, Yang HC, Kuo YT, et al:The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 3:e186, 2014.
PubMed
8) Sakuma T, Masaki K, Abe-Chayama H, et al:Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus. Genes Cells 21:1253-1262, 2016.
PubMed
9) Pacesa M, Lin CH, Clery A, et al:Structural basis for Cas9 off-target activity. Cell 185:4067-4081. e21, 2022.
 
10) Kostyushev D, Kostyusheva A, Brezgin S, et al:Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Sci Rep 9:1847, 2019.
PubMed
11) Schiwon M, Ehrke-Schulz E, Oswald A, et al:One-Vector System for Multiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNA Utilizing High-Capacity Adenoviral Vectors. Mol Ther Nucleic Acids 12:242-253, 2018.
PubMed
12) Seeger C, Sohn JA:Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA. Mol Ther 24:1258-1266, 2016.
PubMed
P.302 掲載の参考文献
1) Tanaka J, Kurisu A, Ohara M, et al:Burden of chronic hepatitis B and C infections in 2015 and future trends in Japan:A simulation study. Lancet Reg Health West Pac 22:100428, 2022.
 
2) B型肝炎治療ガイドライン(第4版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2022. [https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v4.pdf]
 
3) Haber P, Schillie S:Hepatitis B. In:Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases, 14th ed(ed by Hall E, Wodi AP, Hamborsky J, et al), p143-164, Public Health Foundation, Washington DC, 2021.
 
4) Fattovich G, Bortolotti F, Donato F:Natural history of chronic hepatitis B:special emphasis on disease progression and prognostic factors. J Hepatol 48:335-352, 2008.
PubMed
5) Martinot-Peignoux M, Boyer N, Colombat M, et al:Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J Hepatol 36:543-546, 2002.
PubMed
6) Ito K, Yotsuyanagi H, Sugiyama M, et al:Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol 31:180-189, 2016.
PubMed
7) Ito K, Yoneda M, Sakamoto K, et al:Virological and Clinical Characteristics of Hepatitis B Virus Genotype A. J Gastroenterol 53:18-26, 2018.
 
8) Sugiyama M, Tanaka Y, Kato T, et al:Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 44:915-924, 2006.
PubMed
9) Ito K, Yotsuyanagi H, Yatsuhashi H, et al:Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. Hepatology 59:89-97, 2014.
PubMed
10) Sakamoto K, Ito K, Yotsuyanagi H, et al:Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan. J Gastroenterol 57:971-980, 2022.
PubMed
11) 慢性肝炎・肝硬変の診療ガイド2016(日本肝臓学会 編), p11, 文光堂, 2016.
 
12) Pollicino T, Saitta C, Raimondo G:Hepatocellular carcinoma:the point of view of the hepatitis B virus. Carcinogenesis 32:1122-1132, 2011.
PubMed
13) Marusawa H, Uemoto S, Hijikata M, et al:Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31:488-495, 2000.
PubMed
P.307 掲載の参考文献
1) Thimme R, Wieland S, Steiger C, et al:CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68-76, 2003.
PubMed
2) Guidotti LG, Chisari FV:Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 1:23-61, 2006.
PubMed
3) Chisari FV:Rous-Whipple Award Lecture. Viruses, immunity, and cancer:lessons from hepatitis B. Am J Pathol 156:1117-1132, 2000.
PubMed
4) Fisicaro P, Valdatta C, Massari M, et al:Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 138:682-693. e4, 2010.
 
5) Beasley RP, Hwang LY, Lin CC, et al:Incidence of hepatitis B virus infections in preschool children in Taiwan. J Infect Dis 146:198-204, 1982.
PubMed
6) Stevens CE, Beasley RP, Tsui J, et al:Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 292:771-774, 1975.
PubMed
7) 国立感染症研究所:B型肝炎ワクチンに関するファクトシート(平成22年7月7日版), 2010. [http://www.mhlw.go.jp/stf/shingi/2r9852000000bx23-att/2r9852000000bxqf.pdf]
 
8) Ito K, Yotsuyanagi H, Sugiyama M, et al:Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. J Gastroenterol Hepatol 31:180-189, 2016.
PubMed
9) Tamada Y, Yatsuhashi H, Masaki N, et al:Hepatitis B virus strains of subgenotype A2 with an identical sequence spreading rapidly from the capital region to all over Japan in patients with acute hepatitis B. Gut 61:765-773, 2012.
PubMed
10) Kobayashi M, Arase Y, Ikeda K, et al:Clinical features of hepatitis B virus genotype A in Japanese patients. J Gastroenterol 38:656-662, 2003.
PubMed
11) 柘植雅貴, 茶山一彰:HBc 抗体(IgM・HBc 抗体, IgA・HBc 抗体を含む). 日本臨牀 62(増刊:ウイルス性肝炎(下)):129-133, 2004.
 
12) Umemura T, Tanaka E, Kiyosawa K, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-e56, 2008.
PubMed
P.312 掲載の参考文献
1) Velkov S, Ott JJ, Protzer U, et al:The global hepatitis B virus genotype distribution approximated from available genotyping data. Genes (Basel) 9:465, 2018.
 
2) Orito E, Ichida T, Sakugawa H, et al:Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan. Hepatology 34:590-594, 2001.
PubMed
3) Matsuura K, Tanaka Y, Hige S, et al:Distribution of hepatitis B virus genotypes among patients with chronic infection in Japan shifting toward an increase of genotype A. J Clin Microbiol 47:1476-1483, 2009.
 
4) Tsushima K, Tsuge M, Hiraga N, et al:Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice. J Gastroenterol 54:650-659, 2019.
 
5) Shiina S, Fujino H, Uta Y, et al:Relationship of HBsAg subtypes with HBeAg/anti-HBe status and chronic liver disease. Part I:Analysis of 1744 HBsAg carriers. Am J Gastroenterol 86:866-871, 1991.
PubMed
6) Sumi H, Yokosuka O, Seki N, et al:Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 37:19-26, 2003.
 
7) Kao JH, Chen PJ, Lai MY, et al:Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 118:554-559, 2000.
PubMed
8) Sugauchi F, Orito E, Ichida T, et al:Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 124:925-932, 2003.
PubMed
9) Thakur V, Guptan RC, Kazim SN, et al:Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol 17:165-170, 2002.
PubMed
10) Wai CT, Fontana RJ, Polson J, et al:Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States. J Viral Hepat 12:192-198, 2005.
PubMed
11) Sanchez-Tapias JM, Costa J, Mas A, et al:Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology 123:1848-1856, 2002.
 
12) Chu CJ, Keeffe EB, Han SH, et al:Hepatitis B virus genotypes in the United States:results of a nationwide study. Gastroenterology 125:444-451, 2003.
PubMed
13) Livingston SE, Simonetti JP, Bulkow LR, et al:Clearance of Hepatitis B e Antigen in Patients With Chronic Hepatitis B and Genotypes A, B, C, D, and F. Gastroenterology 133:1452-1457, 2007.
 
14) Rodriguez-Frias F, Buti M, Jardi R, et al:Hepatitis B virus infection:precore mutants and its relation to viral genotypes and core mutations. Hepatology 22:1641-1647, 1995.
PubMed
15) Hussain M, Chu CJ, Sablon E, et al:Rapid and sensitive assays for determination of hepatitis B virus (HBV) genotypes and detection of HBV precore and core promoter variants. J Clin Microbiol 41:3699-3705, 2003.
PubMed
16) Lin CL, Liu CH, Chen W, et al:Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J Gastroenterol Hepatol 22:1098-1103, 2007.
 
17) Wong GL, Chan HL, Yiu KK, et al:Meta-analysis:The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 37:517-526, 2013.
PubMed
18) McMahon BJ, Nolen LD, Snowball M, et al:HBV Genotype:A Significant Risk Factor in Determining Which Patients With Chronic HBV Infection Should Undergo Surveillance for HCC:The Hepatitis B Alaska Study. Hepatology 74:2965-2973, 2021.
PubMed
19) Janssen HL, van Zonneveld M, Senturk H, et al:Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B:a randomised trial. Lancet 365:123-129, 2005.
PubMed
20) Flink HJ, Hansen BE, Heathcote EJ, et al:Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol 101:2523-2529, 2006.
PubMed
21) Buster EH, Flink HJ, Cakaloglu Y, et al:Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135:459-467, 2008.
PubMed
22) Lau GKK, Piratvisuth T, Luo KX, et al:Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B. N Engl J Med 352:2682-2695, 2005.
PubMed
23) Bonino F, Marcellin P, Lau GK, et al:Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 56:699-705, 2007.
PubMed
24) Akuta N, Suzuki F, Kobayashi M, et al:The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38:315-321, 2003.
PubMed
25) Zollner B, Petersen J, Schroter M, et al:20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet 357:934-935, 2001.
PubMed
26) Westland C, Delaney W 4th, Yang H, et al:Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 125:107-116, 2003.
PubMed
27) Sherman M, Yurdaydin C, Simsek H, et al:Entecavir therapy for lamivudine-refractory chronic hepatitis B:improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 48:99-108, 2008.
PubMed
28) Marcellin P, Ahn SH, Ma X, et al:Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology 150:134-144. e10, 2016.
 
P.319 掲載の参考文献
1) Akrami H, Monjezi MR, Ilbeigi S, et al:The Association Between Hepatitis B Virus Mutations and the Risk of Liver Disease and Hepatocellular Carcinoma. Curr Mol Med 22:514-523, 2022.
PubMed
2) Liu S, Zhang H, Gu C, et al:Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma:a meta-analysis. J Natl Cancer Inst 101:1066-1082, 2009.
PubMed
3) Yin J, Xie J, Zhang H, et al:Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol 45:1063-1071, 2010.
PubMed
4) Hosseini SY, Sanaei N, Fattahi MR, et al:Association of HBsAg mutation patterns with hepatitis Binfection outcome:Asymptomatic carriers versus HCC/cirrhotic patients. Ann Hepatol 18:640-645, 2019.
 
5) Mun HS, Lee SA, Kim H, et al:Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections. J Virol 85:123-132, 2011.
PubMed
6) Yang JC, Teng CF, Wu HC, et al:Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49:1962-1971, 2009.
PubMed
7) Lazarevic I, Banko A, Miljanovic D, et al:Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses 11:778, 2019.
PubMed
8) Asahina Y, Enomoto N, Ogura Y, et al:Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. J Hepatol 25:787-794, 1996.
PubMed
9) Osiowy C, Villeneuve JP, Heathcote EJ, et al:Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2) . J Clin Microbiol 44:1994-1997, 2006.
PubMed
10) Caligiuri P, Cerruti R, Icardi G, et al:Overview of hepatitis B virus mutations and their implications in the management of infection. World J Gastroenterol 22:145-154, 2016.
PubMed
11) Yang Z, Zhuang L, Lu Y, et al:Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma:a meta-analysis. Oncotarget 7:12525-12536, 2016.
 
12) Yang HI, Yeh SH, Chen PJ, et al:Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 100:1134-1143, 2008.
PubMed
13) Hayashi S, Khan A, Simons BC, et al:An Association Between Core Mutations in Hepatitis B Virus Genotype F1b and Hepatocellular Carcinoma in Alaskan Native People. Hepatology 69:19-33, 2019.
 
14) Sekiba K, Otsuka M, Funato K, et al:HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. J Hepatol 76:53-62, 2022.
 
15) Wang Y, Lau SH, Sham JS, et al:Characterization of HBV integrants in 14 hepatocellular carcinomas:association of truncated X gene and hepatocellular carcinogenesis. Oncogene 23:142-148, 2004.
PubMed
16) Jang JW, Chun JY, Park YM, et al:Mutational complex genotype of the hepatitis B virus X/precore regions as a novel predictive marker for hepatocellular carcinoma. Cancer Sci 103:296-304, 2012.
PubMed
P.325 掲載の参考文献
1) Kamatani Y, Wattanapokayakit S, Ochi H, et al:A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 41:591-595, 2009.
PubMed
2) Mbarek H, Ochi H, Urabe Y, et al:A genome-wide association study of chronic hepatitis B identified novel risk locus in a Japanese population. Hum Mol Genet 20:3884-3892, 2011.
 
3) Png E, Thalamuthu A, Ong RT, et al:A genome-wide association study of hepatitis B vaccine response in an Indonesian population reveals multiple independent risk variants in the HLA region. Hum Mol Genet 20:3893-3898, 2011.
 
4) Wu TW, Chen CF, Lai SK, et al:SNP rs7770370 in HLA-DPB1 loci as a major genetic determinant of response to booster hepatitis B vaccination:results of a genome-wide association study. J Gastroenterol Hepatol 30:891-899, 2015.
 
5) Sakai A, Noguchi E, Fukushima T, et al:Identification of amino acids in antigen-binding site of class II HLA proteins independently associated with hepatitis B vaccine response. Vaccine 35:703-710, 2017.
PubMed
6) Nishida N, Sugiyama M, Sawai H, et al:Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. Hepatology 68:848-858, 2018.
PubMed
7) Sawai H, Nishida N, Khor SS, et al:Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. Sci Rep 8:7958, 2018.
 
8) Trinks J, Nishida N, Hulaniuk ML, et al:Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. Liver Int 37:1476-1487, 2017.
 
9) Mohammadi H, Alavian SM, Sharafi H:Association of single nucleotide polymorphisms in immune-related genes with spontaneous HBsAg seroconversion:A systematic review and meta-analysis. Int Immunopharmacol 110:108982, 2022.
PubMed
10) Tseng TC, Yu ML, Liu CJ, et al:Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Antivir Ther 16:629-637, 2011.
 
11) Brouwer WP, Sonneveld MJ, Tabak F, et al:Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther 40:811-818, 2014.
PubMed
12) Tangkijvanich P, Chittmittraprap S, Poovorawan K, et al:A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B:Role of host and viral factors associated with treatment response. J Viral Hepat 23:427-438, 2016.
PubMed
13) Cheng L, Sun X, Tan S, et al:Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients. Hepatol Res 44:1000-1007, 2014.
PubMed
14) Su TH, Yang HC, Tseng TC, et al:Distinct relapse rates and risk predictors aer discontinuing tenofovir and entecavir therapy. J Infect Dis 217:1193-1201, 2018.
 
15) O'Brien TR, Kohaar I, Pfeiffer RM, et al:Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun 12:428-433, 2011.
PubMed
16) Thomas R, Thio CL, Apps R, et al:A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol 86:6979-6985, 2012.
PubMed
17) Nishida N, Sawai H, Kashiwase K, et al:New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. Plos One 9:e86449, 2014.
PubMed
18) Niehrs A, Garcia-Beltran WF, Norman PJ, et al:A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44. Nat Immunol 20:1129-1137, 2019.
PubMed
P.334 掲載の参考文献
1) Lok AS, Liang RH, Chiu EK, et al:Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188, 1991.
PubMed
2) Umemura T, Tanaka E, Kiyosawa K, et al:Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47:e52-56, 2008.
PubMed
3) Hui CK, Cheung WW, Zhang HY, et al:Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131:59-68, 2006.
PubMed
4) Kusumoto S, Tanaka Y, Mizokami M, et al:Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90:13-23, 2009.
PubMed
5) 坪内博仁, 桶屋 真, 井戸章雄, ほか:劇症肝炎及び遅発性肝不全(LOHF:late onset hepatic failure)の全国統計(2006年). 厚生労働科学研究費補助金難治性疾患克服研究事業難治性の肝・胆道疾患に関する調査研究 平成19年度研究報告, p83-94, 2008.
 
6) B型肝炎治療ガイドライン(第4版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2022.
 
7) 森 尚義, 白木克哉:多職種連携によるHBV再活性化予防システムの構築. 感染症学雑誌 92:568-570, 2018.
 
8) 野ツ俣和夫, 松川弘樹, 山川元太, ほか:免疫抑制・化学療法施行例におけるHBV再活性化発生の現状と効率的予防管理-病院における8年間の前向き検討-. 日消誌 118:1038-1046, 2021.
Medical*Online
P.339 掲載の参考文献
1) Sarin SK, Kumar M, Lau GK, et al:Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update. Hepatol Int 10:1-98, 2016.
PubMed
2) Tan A, Koh S, Bertoletti A:Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med 5:a021428, 2015.
PubMed
3) Hui RW, Mak LY, Seto WK, et al:RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol 28:408-424, 2022.
PubMed
4) Liang XH, Sun H, Nichols JG, et al:RNase H1-Dependent Antisense Oligonucleotides Are Robustly Active in Directing RNA Cleavage in Both the Cytoplasm and the Nucleus. Mol Ther 25:2075-2092, 2017.
PubMed
5) Yuen MF, Heo J, Jang JW, et al:Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B:a phase 2 randomized controlled trial. Nat Med 27:1725-1734, 2021.
PubMed
6) Yuen MF, Lim SG, Plesniak R, et al:Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med 387:1957-1968, 2022.
PubMed
7) Yuen MF, Locarnini S, Lim T, et al:Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol 77:1287-1298, 2022.
PubMed
P.344 掲載の参考文献
1) B型肝炎治療ガイドライン(第4版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2022.
 
2) Yeo YH, Ho HJ, Yang HI, et al:Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection:A Systematic Review and Meta-analysis. Gastroenterology 156:635-646. e9, 2019.
 
3) Marcellin P, Gane E, Buti M, et al:Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet 381:468-475, 2013.
PubMed
4) Liaw YF, Sung JJ, Chow WC, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
5) Suzuki F, Hosaka T, Suzuki Y, et al:Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol 54:182-193, 2019.
PubMed
6) Koike K, Suyama K, Ito H, et al:Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients. Hepatol Res 48:59-68, 2018.
PubMed
7) Chen MB, Wang H, Zheng QH, et al:Comparative efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive chronic hepatitis B:A systematic review and meta-analysis. PLoS One 14:e0224773, 2019.
PubMed
8) Agarwal K, Brunetto M, Seto WK, et al:96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68:672-681, 2018.
PubMed
9) Tenney DJ, Rose RE, Baldick CJ, et al:Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 49:1503-1514, 2009.
PubMed
10) Zoulim F, Bialkowska-Warzecha J, Diculescu MM, et al:Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure. Hepatol Int10:779-788, 2016.
 
11) Lim YS, Lee YS, Gwak GY, et al:Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B:3-year trial. Hepatology 66:772-783, 2017.
PubMed
12) Byun KS, Choi J, Kim JH, et al:Tenofovir Alafenamide for Drug-Resistant Hepatitis B:A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. Clin Gastroenterol Hepatol 20:427-437. e5, 2022.
 
13) Ogawa E, Nakamuta M, Koyanagi T, et al:Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B:week 144 results from a real-world, multicentre cohort study. Aliment Pharmacol Ther 56:713-722, 2022.
PubMed
14) Marcellin P, Wong DK, Sievert W, et al:Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int 39:1868-1875, 2019.
PubMed
15) Hwang EG, Jung AE, Yoo JJ:Risk of dyslipidemia in chronic hepatitis B patients taking tenofovir alafenamide:a systematic review and meta-analysis. Hepatol Int, 2023. (DOI:10. 1007/s12072-023-10528-7)
 
P.350 掲載の参考文献
1) Hosaka T, Suzuki F, Kobayashi M, et al:Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B:results from a nine-year longitudinal study. J Gastroenterol 48:930-941, 2013.
PubMed
2) Suzuki F, Hosaka T, Suzuki Y, et al:Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients in Japan. J Gastroenterol 54:182-193, 2019.
PubMed
3) Liaw YF, Sung JJY, Chow WC, et al:Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531, 2004.
PubMed
4) Hosaka T, Suzuki F, Kobayashi M, et al:Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58:98-107, 2013.
PubMed
5) Singal AK, Salameh H, Kuo YF, et al:Meta-analysis:the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 38:98-106, 2013.
PubMed
6) Yang HI, Yeh ML, Wong GL, et al:Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis 221:389-399, 2020.
 
7) Hosaka T, Suzuki F, Kobayashi M, et al:HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 30:1461-1470, 2010.
PubMed
8) Testoni B, Lebosse F, Scholtes C, et al:Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol 70:615-625, 2019.
PubMed
9) Hosaka T, Suzuki F, Kobayashi M, et al:Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues. Aliment Pharmacol Ther 49:457-471, 2019.
PubMed
10) Hsu YC, Suri V, Nguyen MH, et al:Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 162:1160-1170. e1, 2022.
 
11) Inoue T, Kusumoto S, Iio E, et al:Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 75:302-310, 2021.
PubMed
12) Hosaka T, Suzuki F, Kobayashi M, et al:Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir. Hepatol Commun 6:36-49, 2022.
PubMed
P.355 掲載の参考文献
1) B型肝炎治療ガイドライン(第4版)(日本肝臓学会 肝炎診療ガイドライン作成委員会 編), 2022. [https://www.jsh.or.jp/lib/files/medical/guidelines/jsh_guidlines/B_v4.pdf]
 
2) 黒崎雅之:B型慢性肝炎に対するペグインターフェロン単独療法と核酸アナログ併用療法. 日本臨牀 73(増刊:新ウイルス性肝炎学):466-470, 2015.
 
3) Suzuki F, Arase Y, Akuta N, et al:Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan. J Gastroenterol 39:969-974, 2004.
PubMed
4) Sonneveld MJ, Wong VW, Woltman AM, et al:Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 142:513-520. e1, 2012.
 
5) Enomoto M, Nishiguchi S, Tamori A, et al:Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. Hepatol Res 48:459-468, 2018.
 
6) Matsumoto A, Nishiguchi S, Enomoto H, et al:Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol 53:247-257, 2018.
PubMed
7) NAFLD/NASH 診療ガイドライン 2020[改訂第2版](日本消化器病学会・日本肝臓学会 編), p28-29, 南江堂, 2020.